Charles Adams’ research areas include exchange rates; financial market developments and issues; monetary policy formulation; and regional economic integration and co-operation. He has published widely in various journals and recently co-edited a book on financial and corporate restructuring in the aftermath of the Asian crisis. For close to 25 years, Charles Adams was an official at the International Monetary Fund (IMF) where he worked on the IMF’s World Economic Outlook and International Capital Markets Reports and was, until last year, Assistant Director at the IMF’s Regional Office for Asia and the Pacific located in Tokyo. During the last few years, he represented the IMF at regional policy meetings of APEC, ASEAN, ASEAN +3, EMEAP and SEACEN and also represented the IMF on the Financial Stability Forum Working Group on Highly Leveraged Institutions. Since leaving the IMF, Charles Adams has been a visiting professor at Singapore Management University and a consultant in the Office of Regional Economic Integration at the Asian Development Bank.

Jon has over 30 years experience in investment management, with extensive experience in all aspects of superannuation fund management. He was the Fund Manager of the Meat Industry Employees Superannuation Fund from 1999 to 2008, Jon remains a part time investment manager for the Fund. Prior to that Jon was Director and Asset Consultant within the Corporate Finance section of PriceWaterhouseCoopers, and Manager Investment Consultant at Sedgewick Noble Lowndes. Jon holds a number of Board positions: - Chairman, Global Masters Fund Limited - Director, Phosphagenics Limited - Director African Enterprise Australia and New Zealand - Member and International Treasurer of the African Enterprise International Partnership Board - Director of Hawkesbridge Private Equity Pty Ltd - Director TPCG - Director Austcorp Group Ltd

Shintaro Asako is the Vice President and Chief Financial Officer of MediciNova Inc. San Diego, USA., a life sciences company listed on the Osaka Stock Exchange and the NASDAQ. Mr. Asako joined MediciNova in July 2005and before that he was an audit senior manager at KPMG LLP (KPMG). Prior to joining KPMG, he spent four years with Arthur Andersen LLP. Mr. Asako is a graduate of the Leventhal School of Accounting at the University of Southern California. Mr. Asako is a certified public accountant of the state of California and a member of the American Institute of Certified Public Accountants.

Lee E. Babiss, Ph.D., is Global Head, Pharma Research at Roche in Basel Switzerland where he is responsible for leading and managing Research within Roche Pharma across the five Disease Biology Areas: virology (Palo Alto, California), oncology (Nutley, NJ), metabolic diseases (Basel, Switzerland), inflammation (Palo Alto), and central nervous system (Basel), as well as research in Shanghai, China. Babiss is also a member of the Roche Pharma Executive Committee, Strategic Portfolio Committee and Chairs the Roche R&D Center China Scientific Board. Prior to July 2007, Babiss was vice president, Preclinical Research and Development for Roche in Nutley, N.J., where he was responsible for developing and directing oncology, metabolic diseases and inflammation research strategy. As a member of the International Research Management Team, he was involved in developing global research strategy, and Chaired the Roche Biomarker Leadership Team, a cross-divisional effort within the pharmaceuticals and diagnostics divisions that develops and implements the company’s biomarker strategy. Prior to joining Roche, Babiss was vice president of Biological Sciences and Genetics at Glaxo Wellcome where he focused on the development of antisense technology and cancer therapeutics, headed the Department of Molecular Cell Biology, and played a key role developing and implementing the Cell Cycle Program. Babiss was also a member of the U.S. Research Senior Management Team, which formulated and implemented Glaxo’s U.S. research strategy and was involved in creating the Glaxo Wellcome Corporate Genetic Strategy, which led to the creation of the company’s Genetics Division. Babiss attended graduate school at Columbia University, College of Physicians and Surgeons, in New York, where he earned his Ph.D. in Microbiology in 1982 studying DNA tumor viruses. He then began his postdoctoral career at the Rockefeller University in New York where he studied the molecular regulation of hepatocyte gene expression. Later, Babiss was promoted to assistant professor in Cell Biology, studying adenovirus genetics. An author on more than 70 publications, Babiss currently serves on the board of the Center for Advanced Biotechnology and Medicine at UMDNJ, the Finance Board of the American Society of Microbiology, the Biotechnology Industry Organization, the Scientific Board of the Pharmaceutical Research and Manufacturers of America, and the R&D Council of New Jersey.

Mark Bamforth has responsibility for Genzyme’s global GMP manufacturing sites located in Europe, the USA, Australia and China, and for the centralized support functions of Quality and Technical Operations and Materials Management. He has responsibility for leading the Corporate supply chain and capacity infrastructure strategy which manages an investment of around $600M p.a. to develop internal manufacturing capacity and infrastructure. Mark is also responsible for the Pharmaceutical Business Unit which has a manufacturing operation in Liestal, Switzerland and sells specialty chemicals and drug delivery technologies to the biotechnology and pharmaceutical industry. Before joining Genzyme in 1988, Mark worked as a Drilling Engineer in the North Sea offshore oil industry and then as a Chemical Engineer in the whisky industry. Mark has a BS in Chemical Engineering from Strathclyde University and an MBA from Henley Business School. He serves on the Massachusetts Biotechnology Council Board and is chair of the Economic Development sub-committee, University College London Department of Biochemical Engineering’s Advisory Board and on Scottish Enterprise’s International Advisory Board.

Harsha is a transaction advisory specialist and has more than 15 years of experience with Ernst & Young in Singapore and Colombo offices working in Transaction Advisory Services (TAS) as well as Assurance and Advisory Business Services. Harsha has been involved in a variety of engagements relating to a wide range of clients including private businesses, investment banks, private equity funds, public listed companies and statutory boards. The nature of the engagements he has led includes provision of advice relating to debt restructuring, due diligence reviews, financial modelling, valuations, mergers and acquisitions and litigation support. Harsha specializes in valuations, financial modelling, mergers and acquisitions and debt restructuring. He has significant experience in valuation of businesses, shares and intangible assets in a variety of circumstances. In addition to valuations, he has led M&A, financial modelling advisory and restructuring engagements. His key clients include, SPRING Singapore, Neptune Orient Lines, The Straits Trading Company, Singapore Power, Goldtron, Temasek Holdings, ANZ Banking Group and SembCorp Industries.

Dr. Mølskov Bech graduated from Medical Faculty, University of Copenhagen in Denmark in 1985. From 1985-1987 he held a position as research fellow at Department of Pharmacology, University of Aarhus, with special focus on Clinical Pharmacology and a laboratory model of congestive heart failure. After postgraduate training at Hvidovre and Gentofte County Hospital) 1987-1990) he joined Novo Nordisk in 1990 as project manager for a development project (LMW Heparin). Dr. Mølskov Bech has over his 16 years tenure with Novo Nordisk A/S held numerous management positions – both within development and business – and has a broad career having held positions such as International Product Manager; Regional Manager (Asia Pacific Region); Vice President, International Marketing; Vice President Customer Service and Shipping and Project Vice President. In 2002, Dr. Mølskov Bech obtained his MBA from Scandinavian International Management Institute, Copenhagen. Dr. Mølskov Bech has been working is Asia since 2002, when he was appointed Medical Director, Novo Nordisk Asia Pacific. Since November 2003, Dr. Mølskov Bech has been responsible for the clinical development activities for Novo Nordisk in Asia Pacific, Latin America, Africa and Middle East, East and Central Europe, Australia and New Zealand. During this period the number of patients in clinical trials in the Region has more than tripled to around 6000 patients per year. In Marts 2006, Dr. Mølskov Bech was appointed Vice President, International Operations Clinical Development Centre. Dr. Molskov Bech recently relocated to China in order to oversee Novo Nordisk expansion of clinical development activities in China in the coming years. Dr. Mølskov Bech is a member of Novo Nordisk Global Development Management Group. Dr. Molskov Bech has published more than 20 papers and abstracts and has given presentation both in Europe and Asia.

Simeon has been a health and science reporter with Bloomberg News in Singapore for two years, and a journalist for eight. He writes about healthcare-related stocks and investment trends in Asia, and reports on public health issues including infectious disease, health policy and new medical research. His interests include the changing landscape of healthcare in China, and the growth of medical-device companies there; counterfeit medicines and their potential impact on drug-resistance; and disease trends in Asia, including HIV, malaria, dengue, influenza, cancers, and diabetes.

Kim Bill has over 20 years of international experience in the pharmaceutical and biotech industry in Scientific Affairs, Regulatory, Marketing, Business and Corporate Development. She joined the pharmaceutical industry in 1984, as Marketing Executive for Diethlem Pte Ltd, the largest pharma distributor in Asia. She then joined Les Laboratories Servier, Paris in Marketing, before moving to Serono (MerckSerono) in the Asia-Pacific, European and International Operations in Sales and Marketing and Management positions, including setting up subsidiaries in the then, socialist Central Europe and the USSR. In 1998, she joined Debiopharm, a drug development company in Lausanne, Switzerland where she held the position of Vice-President, Business Development, Licensing and Legal Affairs and a member of the Management Board. Currently Kim Bill holds an interesting and challenging portfolio of functions. She is Vice-President, Corporate Development at the Debiopharm Corporate Group level where she is responsible for investment opportunities for the 5 companies of Debiopharm. Kim also founded her own consultancy company, Creative Business Solutions and provides Corporate and Business advice on deal structures and business-to-business interactions as well as secure Dataroom facilities to the industry. She is on the Board of Directors of Aurigene, a fully integrated drug discovery biotech in Bangalore, India. Kim Bill graduated from the National University of Singapore with a degree in Pharmacy. Later on she earned a Masters in Business Administration at the University of Hull in the UK and General and Marketing Management with Stanford University in the US and Bocconi University in Italy. In April 2006, she was nominated one of three most successful women in biotech by AEGFI, a respected daily Swiss French financial newspaper.

Chief Scientific Officer and Member of the Management Committee since September 2002. After the acquisition of Celltech Biologics by Lonza Group in 1996 he assumed the position of Head of Research and Development at Lonza Biologics plc. Joined Celltech in 1981 and held various positions and became Director of Development. Worked as a Senior Scientist at Tate and Lyle and as a Research Investigator at G.D. Searle. Holds various honorary positions including Visiting Professor of Biotechnology at the University of Reading and Visiting Professor in the Biochemical Engineering Department, University College London. He is a member of the advisory board in the department of Biochemical Engineering, University College London.

David R Blake is a co-founder and co-editor of Bioshares, an independent biotech and pharmaceutical stock report. Bioshares was launched in 2000 and has consolidated its position as Australia's leading weekly independent source of analysis of company activities and sector trends. David was educated at the University of Queensland, from where he received a B.A, majoring in politics and economics and the University of Melbourne, where he completed a Post Graduate Diploma in Economics. He has also received a Graduate Diploma in Applied Finance and Investment from the Securities Institute of Australia. He is Fellow of the Financial Service Institute of Australia

Mr Boon is the Executive Chairman of Exploit Technologies Pte Ltd (ETPL), the strategic marketing and commercialisation arm of Agency for Science, Technology and Research (A*STAR). He is also a board member of the Science and Engineering Research Council and the Biomedical Research Council of A*STAR. He served as the Managing Director of A*STAR from October 2001 and relinquished this position on 31 December 2006. Mr Boon is currently the Chairman of the Executive Committee of Singapore Computer System and Chairman of Nothacker Pte Ltd, a spin-off company under ETPL. He is also the Deputy Chairman of Orangestar Investment Holdings Pte Ltd and Merlion Pharmaceuticals Pte Ltd. He serves on the Boards of the Infocomm Development Authority of Singapore, Singapore Utilities International Pte Ltd and a member of the National University of Singapore Dean's Advisory Board and the INSEAD Singapore National Council. Mr Boon is a Fellow at the Singapore Institute of Directors and the Institute of Certified Public Accountants of Singapore and a Registered Professional Engineer. Prior to joining A*STAR, Mr Boon was CEO and Deputy Chairman of ST Engineering Pte Ltd, and concurrently the Chief Financial Officer of Singapore Technologies. He was awarded the Singapore Business Award for Outstanding CEO, one of Singapore’s prestigious business awards in 2000. Mr Boon continues to serve as an Advisor to ST Engineering Pte Ltd and ST Asset Management Ltd.

Bill is currently a Director in Pfizer's Venture Investments Group, the venture capital arm of Pfizer Inc.. Since joining Pfizer in early 2004, Bill has played an instrumental role in numerous new Pfizer venture investments. Bill currently serves as a board observer for Aureon Laboratories, Avid Radiopharmaceuticals, Evolution Benefits, HandyLab, HD Biosciences, M2S, Nodality, and Supplyscape. Prior to joining Pfizer, Bill worked in Business Development at Galileo Pharmaceuticals and at IntraBiotics Pharmaceuticals. Prior to his roles in business development, Bill was an analyst at Bay City Capital, a leading life sciences merchant bank. At Bay City, he evaluated numerous investment opportunities in biopharmaceuticals and assisted portfolio companies in their fundraising activities. Mr. Burkoth received a BS in chemistry from Whitman College. Pfizer Venture Investments is part of Pfizer Inc, which discovers, develops and markets leading prescription medicines for humans and animals. The Group invests in companies that develop or market technologies, products or services that could advance Pfizer’s commercial interests and that may dramatically change the dynamics involved in commercializing pharmaceutical products. While our primary objectives are strategic in nature, the potential for strong financial returns is one of the key selection criteria we use in making our investment decisions.

Dr Carrano BSc (Hons) PhD MBA is General Manager of Phase Forward Australia and Regional Director, with responsibility for operations in Australia and Asia (excluding Japan). He has built a flexible and efficient team based in Sydney aimed at meeting the specific needs of regional clients. In addition to managing operations and business development, he and his team are involved in software development for clinical data management, pharmacovigilance and medical information. Jon is actively involved in industry organizations in Clinical Data Management, Health Informatics, Pharmacovigilance and Strategic Management. He has presented regularly at regional and international conferences such as DIA and ARCS. Jon has a background in biomedical research and biotechnology, having undertaken postgraduate research in immunology and neurobiology at the University of Western Australia and University of Sydney and early biotech companies. In the late 1980’s he became involved in software development for laboratory analysis and in 1990 changed career by joining BBN software, the predecessor company which eventually merged into his current company.

Dr Lily Chan is Chief Executive Officer of NUS Enterprise at the National University of Singapore. She leads NUS Enterprise with vision to inject an enterprise dimension to NUS teaching and research involving the University's students, staff and alumni. In particular, Dr Chan spearheads strategies and initiatives to promote industry collaboration and business ventures for the University. She oversees the functions of the Enterprise Cluster which complements the academic cluster of the University to nurture talents with an entrepreneurial and global mindset. The Enterprise Cluster comprises three main divisions – NUS Overseas Colleges (NOC), Industry Liaison Office (ILO) and NUS Entrepreneurship Centre (NEC), which are supported by Corporate Services and the following Business units – NUS Extension (NEX), NUS Press and NUS Technology Holdings Pte Ltd (NTH). Prior to joining NUS in 2006, Dr Chan held the position of Managing Director, Investments, of Bio*One Capital Pte Ltd, an investment arm of the Singapore Economic Development Board with focus in expanding the growth of biomedical science industry in Singapore. Dr Chan brings with her more than 20 years of biomedical industry experiences, from initiating start-ups, venture investments and active Board involvements in many biotech companies. A company founded under her leadership included ES Cell International Pte Ltd, founded with technologies licensed from NUS, Universities of Monash (Australia) and Hadassah (Israel). Dr Chan obtained her honours degree in Biology, at the Agnes Scott College, Atlanta, Georgia, USA. She completed her PhD (Microbiology and Immunology) in 1981, at the University of Illinois at the Medical Center, Chicago, Illinois, USA. Dr Chan started her career as a research scientist with the NUS Department of Medicine (1981-1983). One of the first research scientists to be hired in the Department, her research focus areas then were hepatitis and liver cancer, epidemiology, tumour markers and diabetes. She went on to become the QC/Technical Manager for Singapore Biotech Pte Ltd, Singapore (1984-1986) and was a postdoctoral research associate with the Department of Pathology, Tufts University, Boston, Massachusetts, USA (1986-1987). During 1987-1995, she assumed positions of increasing responsibilities, from a Manager in product development to subsequently becoming the General Manager (S'pore) and Director of Product Development (USA) for Genelabs Diagnostics Pte Ltd Singapore. Between 1995-1998, she was the Deputy Director, Bioprocessing Technology Centre, NUS (1995-1998). Dr Chan holds two US patents -- for HIV1/HIV2 viral detection kit and method as well as for dengue virus peptides and methods. Both are now commercial products and one has become the confirmatory gold standard for retroviral testings in Europe. She has another patent pending for tuberculosis antigens and novel liver antigens. She has published more than 20 international journal publications.

Michael Chan is currently Sr. Vice President of PQC Consulting, Inc., a California, USA, based consulting firm offering solutions and education to the pharmaceutical and biopharmaceutical industries. PQC Consulting, Inc.'s projects helping a number of Asia-based manufacturing organizations develop their GMP infrastructure. Mike has over 18 years of experience in the pharmaceutical and biotech industry with emphasis in manufacturing, capital projects and strategy development. Mike worked at Amgen, Inc. from 1991 until 2005 and had held various management positions in Contract Manufacturing Operations, Logistics and Capital Projects. He was the CMC Team Leader for Vectibix®, an EGFr antibody and abarelix, a GnRH antagonist peptide. Mike had presented at the annual BIO International conference as well other technical conferences in the subject of CGMP manufacturing and strategy. He has also published several articles for the American Pharmaceutical Outsourcing journal. He received his B.S. in Mechanical Engineering from the Illinois Institute of Technology and his MBA from the UCLA Anderson School of Management.

Arani Chatterjee, MBBS, MPhil, PGCPM joined Panacea Biotec Ltd. in July 2004. Dr. Chatterjee completed his graduation from Christian Medical College, Vellore and post-graduation from National Institute of Mental Health and Neuro Sciences, Bangalore. In addition, he has completed a Post-Graduate Certificate Program in Management from Indian Institute of Management, Indore. Before joining Panacea Biotec, he was a Research Physician at Dr. Reddy’s Laboratories (Discovery Research), Hyderabad for six years. He also has a continuing appointment as a visiting faculty at University of Pune and as a Governing Body member at Institute of Clinical Research (India). His experience includes participation in pre-IND meetings at FDA, regulatory meetings at WHO, scientific advice meetings at Bundesinstituts für Arzneimittel und Medizinprodukte, expert group meetings on review of Indian GCP guidelines, Schedule Y of the Drugs and Cosmetics Rules and National Technology Advisory Group on Immunisation. Dr. Chatterjee has successfully undertaken numerous clinical research projects in India. He has published ten papers in national and international peer-reviewed journals.

Since founding General Biologic in Shanghai in 2002, Mr. Chervenak has advised clients in the pharmaceutical, biotechnology, healthcare, and investment industries. Mr. Chervenak’s areas of focus include strategy development, deal sourcing, due diligence, drug discovery, outsourcing, and industry data. He has published extensively and is a frequent speaker at industry events. Previously, Mr. Chervenak worked as a strategist for Sapient Corporation in New York City and conducted research at New York University Medical Center and the National Institutes of Health. Mr. Chervenak received a BS in Biology from The Pennsylvania State University. General Biologic is an advisory, consulting, and information firm focused on China’s pharmaceutical, biotechnology, and healthcare industries.

Dr. Wei-Kuang Chi, Director of CGMP Biopharmaceutical Pilot Plant Facility, Development Center for Biotechnology (DCB) obtained his M.S in Engineering and Ph.D. in Chemical Engineering from the University of Pennsylvania, Philadelphia, USA. Dr. Chi has over 21 years of experience in biotechnology process development, including mammalian cell culture (CHO, NS0, hybridoma, 293 cell, insect cell etc.), recombinant yeast (Saccharomyces cerevisiae, and Pichia pastoris ), recombinant Escherichia coli, online mass spectrometric off-gas analysis for fed-batch process control, and cell disruption bioseparation technology. He is responsible for the establishment of DCB’s new multi-product CGMP Biopharmaceutical Pilot Plant Facility (BPPF), including design, equipment procurement/installation, validation, GMP quality system setup, analytical method validation, cleaning validation, process validation, and GMP production. This facility CGMP certified by Taiwan Department of Health (DOH) on December 2005 and received DMF with USA FDA on March 2006. The CGMP Biopharmaceutical Pilot Plant Facility has joined Boehringer Ingelheim Biopharmaceuticals Production Alliance Network since May 2007. This CGMP facility has been used to conduct bioprocess scale-up/development and to produce clinical trial material for protein drugs (monoclonal antibodies, recombinant proteins), at least four products have been produced under GMP for IND submissions for Phase I/II clinical trials, has received Taiwan Department of Health IND approval on 2008 for one product and has supported one FDA IND submission on 2008, so far we have conducted process development for over ten products including recombinant proteins and monoclonal antibodies.

Associate Professsor Siow-Ann Chong is the Vice Chairman of Medical Board (Research), Senior Consultant Psychiatrist and Chairman of the Clinical Research Committee at the Institute of Mental Health, as well as a member of the National Medical Research Council of Singapore, and member of the Taskforce of the National Mental Health Policy and Blueprint. He is a Senior Consultant to the Health Service Research and Evaluation Division of the Ministry of Health of Singapore. His research interests are psychosis, psychiatric genetics, epidemiology, and health service research and he has published extensively in these areas. He has won several research awards – including the Inaugural 2006 World Health Organisation and State of Kuwait Prize for Research in Mental Health Promotion, the Clinical Scientist Investigator Award (Category A) from the Biomedical Research Council and National Research Council of Singapore in 2007, the Inaugural 2008 National Medical Excellence Award (team), and the National Healthcare Group of Singapore Distinguished Achievement Award for 2008. He is the Principal Investigator of a 3-year National study assessing the positive and negative mental health status of the Singapore population and the 5-year Translational and Clinical Research Programme in Neuroscience.

Dr Julian Clark is currently Head of Business Development at the Walter and Eliza Hall Institute in Melbourne and for several years has operated his own consulting business, Julian Clark Consulting Pty Ltd. Drawing on more than 25 years of international and cross-cultural business experience in growing and leading technology and healthcare enterprises, large and small, Julian assists organisations with development, commercialisation and organisational strategies to secure sustainable growth. Julian has many years direct experience in developing and commercialising pharmaceuticals, biotechnologies, laboratory instrumentation and industrial processes and consumer products. His broad international experience has been gained through senior positions in Pharmacia, Biochrom and other companies in Sweden, Great Britain, Japan, North America, India and Australia. In recent years he has been particularly active in translating business opportunities across the public-private interface. Julian was also the founding CEO of the Cancer Therapeutics CRC and is a Fellow of the Australian Academy of Technological Sciences and Engineering, and a Member of the Australian Institute of Company Directors. He has a PhD from the University of Glasgow and an Honorary Doctorate from the University of South Australia. Currently, Julian is a Director of Alchemia Limited and Cancer Trials Australia, Chair of the Advisory Board, Sansom Institute, University of South Australia; and an Associate of the Centre for R&D Leadership, University of Melbourne.

Francis P. Crawley is the Executive Director of the Good Clinical Practice Alliance – Europe (GCPA) in Brussels, Belgium and a World Health Organization (WHO) Expert in ethics. He is the co-founder and Steering Committee member of the Strategic Initiative for Developing Capacity in Ethical Review (SIDCER). He is a philosopher specialised in ethical, legal, and regulatory issues concerning health research, teaching at several European, Asian, and Middle East universities. He is the past Secretary General, Ethics Officer, and Chairman of the Ethics Working Party at the European Forum for Good Clinical Practice. He has acted as an author or expert for the leading international and European ethics guidelines, as well as for several in-country guidelines in Asia, Africa, the Americas, and Europe. He is currently Chairman of the Ethical Review Committee of the International Network for Cancer Treatment and Research (INCTR), a member of the INCTR Tissues Committee, and a member of the Ethics Committee of the European Organization for Research & Treatment of Cancer (EORTC). He has been a member of the joint EMVI-AMVTN Ethical Review Committee, a Permanent Liaison Officer to the International Bioethics Committee of UNESCO, and a Contact Officer for the Council of International Organisations of Medical Sciences (CIOMS). For 2006 he was a Visiting Expert in research ethics in the Health Manpower Development Programme, Ministry of Health, Singapore. He is a member of the Scientific Advisory Committee for the World Health Organization’s International Clinical Trials Registry Platform (ICTRP). He also served for four years on the UNAIDS Ethical Review Committee. He is a co-founder and past Steering Committee Member of the Global Forum for Bioethics in Research, a past member of the Committee of Interested Parties of the Centre for the Management of Intellectual Property in Health Research & Development, a past member of the European Science Foundation’s Education Working Group, and a past member of the WHO GCP Handbook drafting committee. In addition, he is a member of the Working Group on Ethics, Union of European Medical Specialists – European Academy of Paediatrics (UEMS-EAP) [formerly CESP], and a partner in the following completed European Commission projects ‘The Development of European Standards on Confidentiality and Privacy in Healthcare among Vulnerable Patient Populations’, ‘Ethical Function in Hospital Ethics Committees’, & ‘Ethical Considerations in Clinical Trial Collaboration with Developing Countries’. He currently represents the GCPA partnership on the European Commission FP7 research projects: European Network for Expertise for Rare Paediatric Neurological Disorders (nEUroped) and Relating Expectations and Needs to the Participation and Empowerment of Children in Clinical Trials (RESPECT). He was the Co-facilitator for the Ethics Roundtable at the Africa Centre for Health & Population Studies in South Africa where he taught a modular GCP course and where he was a member of a DSMB for an HIV vertical transmission study. He is also a member of several regional organizations for ethics in research in Central and Eastern Europe, Asia, Africa, and Latin America. Currently he is Chairman of the Pandemic Advisory Committee to Roche (manufacturer of Tamiflu). He founded the AFROGUIDE Project: Developing Guidelines for Health Research in Africa, with the Cameroon Bioethics Society, the UN Economic Commission for Africa and the African Union. He also serves on several editorial boards for international journals, including Applied Clinical Trials, Pharmaceutical Medicine (formerly the International Journal of Pharmaceutical Medicine), Good Clinical Practice Journal, and the Journal of Empirical Research on Human Research Ethics. He is an Honorary Member of the Faculty of Pharmaceutical Medicine, Royal College of Physicians, United Kingdom.

Professor Paul Herrling is Head of Corporate Research at Novartis, a position he assumed in November 2002. He is also Chairman of the Board of the newly created Novartis Institute for Tropical Diseases in Singapore, a long-term endeavor to advance medical research in the area of tropical infectious diseases, which historically have received little drug-research funding . Prof. Herrling also oversees the Friedrich Miescher Institute in Basel, Switzerland, and the Genomics Institute of the Novartis Research Foundation in La Jolla California and he serves on the boards of several other research institutions. Prior to his current position, Paul Herrling was Head of Global Research at Novartis Pharma and a member of the Pharma Executive Committee (PEC). Paul Herrling is also Professor of Drug Discovery Science at the University of Basel, Switzerland. He obtained his doctorate in 1975 at the University of Zurich and was a post-doctorate fellow at the Neuropsychiatric Institute at the University of California, Los Angeles (UCLA). In addition to a number of scientific editing activities, he serves on several boards, most notably: Board of Trustees of The Scripps Research Institute, La Jolla; he is Vice-President of the Board of the ETH (Swiss Federal Institutes of Technology), Zuerich, and the Scientific Advisory Committee of the Drugs for Neglected Diseases Initiative (DNDi) in Geneva.

John D. Diekman, Ph.D. is a founder and Managing Partner of 5AM Ventures. Prior to founding 5AM, Dr. Diekman was a founder and Managing Director of Bay City Capital, a life sciences investment firm. Previously, Dr. Diekman was Chairman and CEO of Affymetrix, Inc, where he still serves as a Director. Dr. Diekman currently serves as Board Chairman of Ambrx and Phenomix as well as on the Boards of Directors of Antipodean, Ingenuity Systems, Marcadia, PhaseRx and Wildcat Discovery. He is also Vice-Chairman of Singapore's Life Science Fund, Bio*One Capital. He was recently named a Trustee of Princeton University and is also former Trustee of The California Institute of Technology and The Scripps Research Institute, where he served as Chairman. Dr. Diekman holds a B.A. in Chemistry from Princeton University and a Ph.D. in Chemistry from Stanford University. Dr. Diekman is based in the Menlo Park, CA office.

Mr. Dunlop has almost two decades of international experience in evaluating early-stage biotechnology companies. He is Founder and Managing Partner of MASA Life Science Ventures LP, a trans-Pacific venture fund investing in private, high-growth biotechnology and life science companies. Mr. Dunlop currently leads the review and analysis of Fund investment candidates. A former international business and economics analyst with the Center for Strategic & International Studies in Washington, D.C., Mr. Dunlop has private equity and venture capital experience in East Asia, Europe, the U.S. and Israel. Mr. Dunlop received his M.B.A. from Columbia Business School where he was the R.C. Kopf British-American Fellow in international business. He also holds an M.A. with Honors in Political Economy from the University of Glasgow and an M.A. in International Relations from the Maxwell School of Citizenship and Public Affairs at Syracuse University. Mr. Dunlop currently sits on the Boards of Correlogic Systems, Engene Inc., JADO Technologies, Maxcyte Inc. and Potentia Pharmaceuticals.

Dr Dunn has 15 years experience in the field of molecular biology with particular expertise in molecular antibody engineering. She has substantial experience in dealing with international clinical research organisations and commercial manufacturing organisations. Rosanne co-founded IST and has played a major role in setting and achieving the scientific objectives of the Company. This includes the development of broad based Intellectual Property protection resulting in several patent applications. Prior to founding IST, Rosanne was a Senior Research Associate in a R&D syndicated project within UTS. She was involved in the genetic isolation and production of novel recombinant proteins for therapeutic use. Her previous appointment was at the National University of Singapore as a Postdoctoral Fellow in the Bioprocessing Technology Centre. Rosanne was awarded a PhD in antibody engineering from UTS and has published 14 scientific research papers in peer reviewed international journals. She has also been the recipient of UTS research grants and has served on conference committees with the Royal North Shore Hospital.

Dr. Ahmed Emara is the CEO of Jeddah BioCity Holding & Managing Director of a number of affiliated companies. www.jeddahbiocity.com In these roles, he is responsible for overseeing strategy and developing viable investment opportunities in the Healthcare & Life Science markets, with a focus on achieving sustainable returns and contributing to the overall social and economic development of Saudi Arabia, Gulf Countries and Middle East in general. He serves as Director on the Board of ARABIO ( JV vaccines manufacturing), Managing Director of BIOSCAN (premier cancer diagnostic services company), Managing Director of ESD (Medical & Pharmaceutical Waste Treatment Plant), & Managing Director of Rethab (Genetics Diagnosis). Before joining Jeddah BioCity Group in 2007, Dr Ahmed founded & grew Riyadh-based Muse, a Life science-focused boutique service firm www.musehealthcare.com. Prior to that he was with SPIMACO www.spimaco.com.sa , a leading Bio-Pharmaceutical manufacturer in Middle East, where he was responsible for new Business Development & Licensing activities with focus on international markets. Dr. Ahmed worked with Rhone Poulenc Rorer (now part of Sanofi-Aventis) and then with Bayer in Sales, Product Management, Strategic Marketing and Business Development across Canada &Middle East prior to relocating to Saudi Arabia. Dr Ahmed is a Licensed Medical Doctor and holds an MBA from City University of Seattle, USA.

Carl Firth is currently head of Healthcare in Asia Pacific, where he is responsible for advising and executing M&A, equity and debt transactions for healthcare companies across the region. Prior to joining Merrill Lynch, he worked in Singapore as Regional Business Development Director for AstraZeneca Pharmaceuticals, where he looked after business development and strategic projects across the Asia Pacific region. Previously, Carl worked in China for 3 years, where he was responsible for the commercial development of new products, and for business development activities in the China market. Carl has held positions in other commercial areas in the UK, including acquisitions, licensing and competitive intelligence, and has over 5 years of pharmaceutical R&D experience. Carl holds a PhD from Cambridge University and an Executive MBA from London Business School.

Dr Evans received his MD from the University of Virginia and trained in Internal Medicine at UCSF, and in Infectious Diseases back at Virginia. He was on faculty at the University of Utah and the University of Rochester before becoming Infectious Diseases Division Chief and full Professor at the University of California, Davis. His academic research centered on leishmania and vaccine development and led to him joining Vical, a DNA vaccine developer as Chief Medical Officer in 2002. In 2005 he joined the Novartis Institutes for Biomedical Research as Head of Infectious Diseases Translational Medicine and Research. In September 2008 he moved to CNIBR to help in setting up the Translational Science group in China. He has over 100 authored publications.

Dr James Garner completed his medical studies at St Mary’s Hospital Medical School in London. He practiced hospital medicine for a number of years in the United Kingdom and in Australia. After several years as a corporate strategy consultant with Bain & Company in Sydney, James joined Biogen Idec (NASDAQ: BIIB) to assume medical responsibilities for the Asia-Pacific region. During his time with Biogen Idec, he advised on the commercial launch of several novel biologic therapies in nine Asian countries, and also participated in managing regional clinical research and business development activities. Currently, his primary area of responsibility is Progen's global clinical development program and he is also involved in providing medical input into activities such as business development and discovery research. In addition to his medical qualifications, James holds a Bachelor of Sciences (with First Class Honours) from University College, London, and a Master of Arts and a Master of Business Administration from the University of Queensland. He also holds a Graduate Certificate in Applied Finance and Investment from the Financial Services Institute of Australasia. He is a Young Fellow of the Royal Society of Medicine (UK) and a member of the Australian Pharmaceutical Physicians Association.

Kerry Gilzene is a Partner at Santeum Partners - a Swiss based advisory for healthcare investment management and strategy. Kerry is responsible for Strategy, Corporate Development, and Communications. He has 18 years of experience in global healthcare - including GSK Biologicals (global marketing), EVP Aptilon Health, Vice President Global Business Group, Ogilvy Healthworld Asia Pacific, and Senior Vice President / Managing Director of Cline Davis & Mann Europe. Born in London, Kerry holds a B. Eng (Hons) in Biochemical Engineering, a Masters in Advanced Marketing, and he also presents regularly in forums and conferences.

Dr. Ranga Godavarti is currently Associate Director in the Purification Process Development group at Wyeth BioPharma in Andover, MA. His group is responsible for the development, characterization, validation, and technology transfer of purification processes for protein molecules in early and late stages of development. His group is also responsible for providing technical support for commercial manufacturing of Wyeth’s licensed products. Prior to joining Wyeth BioPharma in 1997, he received his Masters degree in Chemical Engineering Practice and a Ph. D in Chemical Engineering from the Massachusetts Institute of Technology (MIT).

Michael Goedde is a Certified Clinical Data Manager with more than 18 years of experience in the pharmaceutical and biotechnology industry. He started his career in 1990 at Hoechst, a predecessor company of Aventis, in Frankfurt (Germany), working as a Study and Project Data Manager. After supporting numerous submissions and leading programs through all stages of clinical development, Michael then chose to join the Aventis Headquarters in Bridgewater, New Jersey (US) as a Global Project Data Manager and Global Therapeutic Area Lead in 2001. In 2005 he accepted an offer to join Kos Pharmaceuticals in Weston, Florida, as an Associate Director of Clinical Data Management, where he was an integral part of building a new CDM department. After the takeover of Kos Pharmaceuticals by Abbott Laboratories in 2007, Michael accepted the position of Director of Clinical Data Management at Human Genome Sciences (HGS) in Rockville, Maryland (USA), which is also the position that he currently holds. Michael holds a degree in Computer Sciences and is a recognized member of the Society for Clinical Data Management (SCDM) and member of the Drug Information Association (DIA). He has presented and chaired sessions on numerous occasions at conferences for those organizations.

Dr. Gottschalk is Group Vice President, Purification Technologies, with a global responsibility for bioseparation products at Sartorius Stedim Biotech. He worked in different capacities for Bayer Health Care from 1991-2004 and became head of the GMP protein purification facility in Wuppertal (Germany). He was responsible for the production of monoclonal antibodies and other recombinant proteins using various expression systems. Dr. Gottschalk holds a Ph.D. in Chemistry from the University of Münster. He is member of BioPharm International’s editorial advisory board and has written one book, five book chapters and many other publications in the areas of biotechnology and somatic gene therapy. In academia Dr. Gottschalk is Head Lecturer at the University of Duisburg–Essen (Germany) and also lectures at the Ecole Polytechnique Fédérale de Lausanne EPFL (Lausanne, Switzerland). Dr. Gottschalk is board member of the VBU Association of German Biotech Companies.

Professor Hart, identified tissue dendritic cells (DC) as a Rhodes Scholar. His experiments indicated their importance in transplantation and led to an interest in DC and their role in immune responses, which continued as Director of the South Island Bone Marrow Transplant Unit (New Zealand). His group defined human DC subsets, contributed fundamental studies on DC differentiation and function and generated several monoclonal antibodies to human DC surface antigens. He developed methods for counting blood DC and changes in DC counts, subsets and activation were associated with disease pathogenesis. This included work describing reversible defects in DC function in cancer patients. Professor Hart is Director of the Mater Medical Research Institute (MMRI, Australia). His DC Program characterized blood DC and started trials using antibody selected blood DC to vaccinate cancer patients. His Program is developing antibodies to DC as novel immunosuppressive agents, which may block immune responses, whilst preserving protective specific T lymphocyte responses. Professor Hart’s DC Program is continuing fundamental DC target discovery to develop human DC targeted therapeutics for applications in cancer, transplantation, autoimmune disease and infection. The MMRI is a core stakeholder in the new Translational Research Institute (Brisbane) and is a partner in the new CRC – Biomarker Translation.

He received Bachelor degree in Chemistry from Lanzhou University, M.Med from Chinese Academy of Medical Sciences, and Ph.D. from National University of Singapore. Thereafter, he was employed as researcher at National Cancer Centre of Singapore and Freiburg University etc. His research includes cancer diagnosis and gene therapy, enzyme research and biomaterials development and application. He possesses over 15 years research experience. He serves as the chief for BioMed investment at Shenzhen Capital Group, the largest VC firm in China. In two years he has closed seven investment deals in healthcare and chemical industry, like HYBio, the No.1 polypeptide drug producer; Beike Biotech, the pioneer on stem cell technology; Beijing Health Guard Biotech, the 2nd generation HPV vaccine developer and Ecomann, the biomaterial PHAs producer. His interest also comprises high-end medical equipment, TCM and diagnostic technology.

Jim Henderson is General Manager Commercialisation – Life Sciences for NewSouth Innovations Pty. Ltd., the commercialisation arm of the University of NewSouth Wales. Taking advantage of extensive U.S. university commercialisation experience, Jim leads a team of Business Development Managers responsible for the commercialisation of all life science projects from the UNSW Science, Engineering and Medical Faculties. In addition to his role at NSi, Jim also sits on the Uniseed Biotechnology Investment Committee. Uniseed is a pre-seed and seed stage venture capital firm supported by the Universities of New South Wales, Queensland and Melbourne and also Westscheme, Western Australia’s largest non-government superannuation fund. Jim is Vice-Chair (Sydney) of Knowledge Commercialisation Australia, the peak body representing organisations and individuals associated with knowledge transfer from Australia’s public sector. Prior to joining NSi, Jim established his experience in university technology commercialisation with two US universities, most recently as a Licensing Officer in the Office of Technology Management at the University of California, San Francisco. UCSF is ranked 9th worldwide by Newsweek International, and the OTM itself ranked as one of the top five technology transfer offices in a 2006 study by the Milkien Institute. While at the OTM, Jim was responsible for managing a portfolio of over 200 distinct inventions, and he led financial and legal negotiations on more than 40 licenses, including six with start-up companies.

Judith is Vice President, External Science, Technology and Licensing Europe and Asia/Pacific for Corporate and Business Development, Bristol-Myers Squibb. Based at the UK headquarters in Uxbridge, United Kingdom, Judith is responsible for the acquisition and licensing of R&D technologies and development stage compounds to support the company's drug discovery and development efforts, with a focus on Europe and Asia Pacific . Recent deals with European companies include those with Solvay Pharmaceuticals of Belgium and Domantis UK. Prior to joining Bristol-Myers Squibb, Judith was Senior Director, Scientific Licensing, Worldwide Business Development at GlaxoSmithKline, where she was responsible for in-licensing for the Respiratory franchise. She also served in the Scientific Licensing Group of SmithKline Beecham, where she was instrumental in completing a number of high-profile deals in the metabolic, respiratory, inflammation, and gastrointestinal therapeutic areas. Judith initially joined SmithKline & French to undertake research in neuroscience and gastrointestinal disease, gaining ten years of research and development experience. Her background also includes academic posts at the School of Pharmacy, University of London; and the Department of Anatomy, University College, London, where the focus of her research was autonomic neurotransmission. Judith holds a BSc Honours. in Pharmacology from the University of Aberdeen, awarded in 1980, and a Ph.D. in Neurobiology from University College, London, awarded in 1984.

Carrie is a co-founder of CM Capital and has led the Life Sciences practice for over 9 years, investing in pharmaceutical, diagnostics and medical device companies. CM Capital Investments is one of Australia’s leading Venture Capital companies focussed on investing in early-stage stage life sciences and telecommunications/IT companies. CM Capital was founded in 1996 and currently has $260 million under management. The inventor of a number of patents, Carrie has been involved in the complete product lifecycle, responsible for the development of new products from basic research to market. She has been a member of a number of Federal and State government boards and advisory bodies, providing advice on the development of the biotechnology and venture capital industries. She is currently a member of the Queensland Government’s Smart State Council and serves on the boards of CathRx Ltd and the Mater Medical Research Institute. Carrie is a fellow of the Academy of Technological Sciences and Engineering (ATSE) and recipient of a Centenary medal.

Jesper Høiland is Senior Vice President in Novo Nordisk; a healthcare company and a world leader in diabetes care. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. With headquarters in Denmark, Novo Nordisk employs approximately 26,000 employees in 79 countries, and markets its products in 179 countries. Jesper is responsible for International Operations; 150 countries – the emerging markets, 40 affiliates, approx 4,000 employees and approx 1.7 billion USD in sales. He started his career as management consultant, and then joined Novo Nordisk more than 20 years ago. He has held numerous different jobs of increasing responsibility and has worked abroad for 15 years in Belgium, Canada, France, Australia and Switzerland. Jesper obtained his MSc in Management from Copenhagen Business School in 1984. He has attended a number of programs at business schools over the years, and he is a frequent presenter at conferences; most recently at • Harvard Business School Health Care Conference in Boston • Pharma 2020 arranged by Economist in London

David Hughes is CEO of BioPharmaceuticals Australia Pty Ltd, a Queensland Government owned company charged with implementation of a major project to build and operate a world-class, fee-for-service biologic drug manufacturing facility for use by Australian biotech companies. David Hughes is an experienced manager in the food and pharmaceutical sectors. David has considerable technical and commercial experience in the scale-up and commercialisation of biotech products. Significantly, David was responsible for the design, construction and commercial operation of Australia’s largest-ever recombinant protein facility. This project, spanning more than 15 years, encompassed the classical developmental path from ’idea to invoice‘. David’s role included direct responsibility for process development, pilot plant design and operation, as well as the design, construction, validation, and commercial operation of a world-scale microbial recombinant protein plant.

A medically trained physician scientist, Professor Itescu has established an outstanding international reputation in the fields of stem cell biology, autoimmune diseases, organ transplantation, and heart failure. He has been a faculty member of Columbia University in New York and of the University of Melbourne. His pioneering work in the use of adult stem cells for heart disease has laid the groundwork for a potential paradigm shift in the treatment of cardiovascular disorders. Professor Itescu has consulted for various international pharmaceutical companies, has been an adviser to biotechnology and health care investor groups, and has served on the Board of Directors of several publicly-listed Australian life sciences companies. In addition, he is the founder and a member of the Board of Directors of Angioblast Systems Inc.

DR. GÜNTER JAGSCHIES holds a Ph.D, in Biochemistry from the University of Münster in Germany. He joined GE Healthcare (GEHC) in 2004 via the acquired former Pharmacia Biotech and Amersham business where he began in 1985 and has held senior commercial, marketing, and R&D management roles. His current position is Director Customer Applications at R&D for GEHC Life Sciences based in Uppsala Sweden, in charge of industrial collaborations and a portfolio of activities to study biopharmaceuticals development workflow as well as the design and economy of manufacturing processes for protein drugs. During his career he has worked as head of Sales in Europe and of Marketing for the global GEHC bioprocessing business. Prior to that he has been in charge of R&D portfolio management with focus on industrial separations technology and has run the company’s Fast Trak customer training centre in Europe. His technical experience includes chromatography process design and technology handling, regulatory issues incl. validation planning, and process economy analysis.

Dr. Jalali obtained his degree, Doctor of Medicine from Medical School in 1988. After completing his doctoral thesis, he worked as Internist in different capacities at various hospitals and subsequently joined Ranbaxy Laboratories Ltd. as Clinical Research Physician. He gained extensive experience in Protocol development in various therapeutic areas and worked on a number of clinical projects (Phase I to IV). In his current position, he is working as Director, Medical Affairs & Clinical Research and guiding his team, with his extensive experience, in the field of clinical research in clinical development and operations.

Liz Jazwinska joined Johnson & Johnson Research Pty Limited (JJR) in 2002. Her primary responsibilities in JJR are to identify and evaluate new business opportunities in the Asia Pacific Region for partnering and licencing into Johnson & Johnson (J&J) global companies. The main focus of partnering is support for the J&J global pharmaceutical sector, this includes partnering and licencing of new chemical entities, chemical libraries and biotechnology platform technologies, research collaborations and outsourcing. In addition, Liz can facilitate links with the medical devices and consumer sectors of J&J to enable companies in the Asia Pacifc region to take their products to the global market place. Prior to joining JJR, Liz held a number of positions in the academic sector and pharmaceutical industry, including Business Development Manager in the Technology Transfer Office of the University of Sydney, Assistant Director in Human Genetics and Pharmacogenetics in SmithKline Beecham in the UK and Senior Research Fellow in Human Genetics at the Queensland Institute of Medical Research. During her academic career Liz authored 62 publications in peer-reviewed journals and continues to act as an expert reviewer for international molecular and medical journals and science funding agencies and is Chair of the Australian Research Council (ARC) College of Experts in Biological Sciences and Biotechnology (the ARC is the major science funding agency in Australia).

Dr. Daewoong Jo, male, immunologist, graduated from Microbiology & Immunology, Vanderbilt University (US) in 2002. He worked for the second biggest pharmaceutical company - YUHAN Corporation R&D Center for 6 years as senior scientist prior to study at Vanderbilt University (1997 – 2002). He also worked at The Wellcome Trust Sanger Institute (UK) and Vanderbilt University Medical School from 2002 to 2006. He published several dozens of papers such as Nature Biotechnology & Nature Medicine in the field of protein-based biotherapeutics discovery/development. He also served technology consultants for several biotechs and pharmas in Korea and the US. Since 2006, he became assistant professor of Chonnam University Medical School, Korea and Founder, CEO of ProCell Therapeutics, Inc. In recent year, he have mastered and focused on new biotechnology for protein-based drug discovery – Macromolecule Intracellular Transduction Technology (MITT) and its application in the fields of cancer, inflammation, obesity, neurodegenerative diseases, osteogenesis and establishment of patient-specific stem cell lines. ProCell Therapeutics, Inc. recently established a strategic partnership with the biggest conglomerate in Korea - SAMSUNG business group.

Tsutomu Kanezaki is Vice President of JAIC Asia Capital Pte Ltd, a wholly owned Singapore subsidiary of Japan Asia Investment Co. (JAIC), a Japanese venture capital listed on Tokyo Stock Exchange 1st Section. Prior to joining Singapore office, he worked in Tokyo Japan for 6 years. He is an original founder of JAIC’s Biotech Investment Division set up in 2001, where he has been involved in more than 50 investment deals both in Japan and overseas. He is currently taking care of 15 portfolio companies directly and involved in the management of three biotech focused funds both in Japan and Singapore. He is now dedicated to facilitating cross-border business partnering between Japanese and Asian biotech and pharmaceutical companies.

Dr. Aditya Kapil has significant life sciences exposure both in India and overseas (UK & US). He leads the early-stage drug discovery deals in Ventureast’s life sciences portfolio. Dr. Kapil has deep experience in setting up Indian operations for overseas companies that benefit from Indian scientific and operational advantages. He has added significant value to such companies, including setting up labs from scratch and hiring key management. Dr. Kapil has helped Ventureast’s portfolio in-license drugs at various stages of development. Dr. Kapil has also forged collaborative deals between drug discovery companies in the West and Indian academia to access Indian synthetic chemistry and molecular biology manpower and skills. Prior to Ventureast, Dr. Kapil was part of the founding team of Jubilant Biosys, a leading Indian biotechnology company with 500+ employees. At Jubilant he led a team of 25 professionals that built the first commercialized gene-protein database out of India. Its current avatar, PathArt®, is used by leading US biotech and pharma companies to alleviate early stage bottlenecks in drug discovery. Dr. Kapil did his Ph.D. in biochemistry at the University of York in UK, followed by post-doctoral stints at the University of Chicago and the National Center for Biological Sciences in India.

Dr. Jan-Anders Karlsson took over the helm as the company’s CEO from January 2005. He has extensive experience in the pharmaceutical industry, with many proven successes in the drug discovery area. Dr. Karlsson will combine his exceptional technical knowledge with his strong business acumen and ability to build entrepreneurial drug discovery cultures, to help S*BIO achieve its vision of becoming an internationally competitive drug discovery and development company. Dr Karlsson is also a member of S*BIO's Board of Directors. Prior to joining S*BIO, Dr. Karlsson was the Executive Vice President, Global Research of Bayer Pharma, where he was a member of the Executive Management Committee and responsible for the company’s global drug discovery organisation.

Brian Kelley is the Senior Director of Bioprocess Development at Genentech, which is responsible for development, validation, and technology transfer of fermentation, cell culture, chromatography and filtration steps for the production of recombinant therapeutic proteins derived from both mammalian and bacterial hosts. Brian joined Genentech in 2007, after working 15 years at Genetics Institute (later purchased by Wyeth). From 1992-2007, he served as an adjunct faculty member of the Chemical and Biological Engineering department at Tufts University, where he taught two graduate classes each year on Principles of Cell and Microbe Cultivation, and Protein Purification. He obtained his B.S. in Chemical Engineering from the University of Wisconsin-Madison, and his Ph.D. from MIT. His interests include experimental design and other statistical methods applied to process development, filtration for cell and virus removal, ultrafiltration of high concentration protein solutions, development of novel affinity chromatography ligands for protein purification, and high throughput chromatographic development. Brian has been active in the American Chemical Society’s Biotechnology division, chairing sessions on biopharmaceutical process validation since 1997. Brian is on the PDA Biotechnology Advisory Board and has chaired the Recovery of Biological Products Board.

Dr. KIM Sung Chun is the Chief Technology Officer of LG Life Sciences. He joined the company after graduating Texas A&M and postdoctoral research at UC Berkeley. His career started as a scientist. He assumed his current position in 2008, having previously involved in business development, and has played a key player in the business development of new chemical drugs including Factive, the first FDA approved drug in Korea. More recently he led the R&D strategic planning division.

Dr. Knight has worked in the pharmaceutical and biotechnology industries for over sixteen years. Prior to joining Fidelity in 2003, Dr. Knight was president and chief operating officer for EPIX Pharmaceuticals in Cambridge, Massachusetts. For six years before joining EPIX, Dr. Knight worked at Arthur D. Little Inc., primarily as a senior consultant in Cambridge and Brussels, Belgium specializing in mergers and acquisitions in the pharmaceutical industry. Prior to 1990, Dr. Knight performed research at AT&T Bell Laboratories (now Lucent Technologies), the National Institutes of Health, and at Yale University. Dr. Knight holds an M.D. from the Yale University School of Medicine and an M.B.A. from the Yale School of Organization and Management. Dr. Knight received a B.S. in biology from Columbia University, graduating summa cum laude and Phi Beta Kappa. Dr. Knight currently serves as Chairman of the Board of Directors for EnVivo Pharmaceuticals. He also serves on the Board of Directors of Ironwood Pharmaceuticals (formerly Microbia), CardioKine, Proteostasis Therapeutics, FoldRX, Bikam Pharmaceuticals, NextWave Pharmaceuticals, Ligocyte Pharmaceuticals and Respivert, Ltd.

Steven Kozlowski is the Director of the Office of Biotechnology Products, Office of Pharmaceutical Science, at the Center for Drugs Evaluation and Research (CDER), FDA. He received his medical degree from Northwestern University and trained in Pediatrics at the University of Illinois. Prior to joining the FDA, Dr. Kozlowski worked as a staff fellow in the Molecular Biology Section of the Laboratory of Immunology, NIAID, NIH. Dr. Kozlowski joined the Division of Monoclonal Antibodies in 1993 and was tenured as a Senior Investigator in 2000. He has been involved in all phases of the regulatory process as a reviewer, from pre-IND product development through inspections, licensing and post approval supplements. Dr. Kozlowski served as the acting Director of the Division of Monoclonal Antibodies from 2004-2005. He has also served as an instructor and as an adjunct clinical reviewer at FDA. Dr. Kozlowski’s research interests include T-lymphocyte activation and migration, and the role of costimulatory/adhesion molecules in cell-cell interactions.

K. Ranga Rama Krishnan, MB ChB, is the Dean at the Duke-NUS Graduate Medical School Singapore (Duke-NUS). He is also Professor and Chairman of the Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, North Carolina. His department of psychiatry includes more than 490 faculty members, conducts more than 270 human-subject studies a year and a similar number of in-vitro and in-vivo animal studies, and receives approximately US$40 million of research funding annually. Dr. Krishnan earned his medical degree and completed a rotating internship at Madras Medical College in Madras, India. He then completed his residency and held a fellowship in neurobiology at the Duke University Medical Center. Dr. Krishnan has created a translational research center for depression in the elderly, the only such center in the United States funded by the National Institutes of Health. Dr. Krishnan is an elected member of the Institute of Medicine – the world’s foremost national resource for independent, scientifically informed analysis and recommendations on human health issues. As a further recognition of his contributions to biomedical science, Dr. Krishnan received the 2007 Distinguished Scientist Award from the American Association for Geriatric Psychiatry. Dr. Krishnan serves or has served on many editorial boards of scientific journals and has received numerous awards.

Por Lai is the Founder of Dephoron Group which explores investment opportunities in life sciences. Between 2000 and 2007, Lai managed President Life Sciences, a prominent Taiwanese corporate fund. Between 1981 and 2000, he held various management positions with US biotech companies including Sequemat, Amgen, Centocor, SBH Sciences, and Protein Institute where he developed biotech instruments, and protein drugs such as rhEPO, rhG-CSF, antibodies and other biologics for human uses, and managed cytokine businesses. In 1992, Lai also co-founded the Kirin Pharmaceuticals Co., Ltd. with Kirin Brewery of Japan and developed its biopharmaceutical markets in the Greater China. Lai has published 40+ scientific papers, patented key biotech patents, and has been an adjunct faculty member with University of Kentucky and Kaohsiung Medical University. He has served as an advisor to various offices of the Taiwan government on biotech programs, and served on the boards of directors of 15+ companies and organizations. He received a pharmacy degree from Kaohsiung Medical College and Ph.D. in Chemistry from Massachusetts College of Pharmacy.

Dr. K. Conrad Lai is New Drug Development Director of Medigen Biotechnology Corp. and Adjunct Assistant Professor at the School of Public Health, National Defense Medical Center (Taiwan). Dr. Lai has had more than 15 years of clinical trials and new drug development experiences such as Clinical Trial Director of Protech Pharmaservices Corp. (PPC), CEO of Clinical Research Management Committee of Chi Mei Medical Center/PPC, Clinical Trial Manager/Clinical Trial Associate of Astra Pharmaceuticals Ltd. Taiwan, and QA Officer/Associate Research Fellow of Development Center of Biotechnology. Dr. Lai received his Ph.D. in Social Biology from the National Defense Medical Center in 2004, M.S. in Pharmacokinetics in 1987 and B.S. in Pharmacy in 1983 from the Taipei Medical College.

Daniel Lee is a Clinical Biochemist and obtained his PhD in Molecular Pathology at the University of Hong Kong in 1988. He worked for Johnson and Johnson Pharmaceutical Research Institute for ten years in inflammation and CNS drug discovery research. He was involved in the late stage discovery and development of Topomax, participated in regulatory work for the in-licensed Reminyl in addition to the many research projects including HTS and bioinformatics activities. He joined Biogen Inc in Boston in 2001 leading a project team focusing on neuroregeneration drug discovery and development. He is a co-inventor on 15 patents and patent applications, publish and review scientific manuscripts, and an active grant reviewer for international grant foundations. He has presented on multiple occasions in international professional meetings and academic institutions. His research interests are neuron-regeneration, neurodegeneration including Alzheimer’s disease and ocular diseases.

Mr. Lee is Co-Chairman and Co-Founder of NAP. He specializes in corporate advisory and capital markets deals. He has over 12 years of private equity and banking experience in which included CFO of VCTG (8228.HK); a partner at Goodman Financial Services and also the Director of Capital Market in Nikko Securities. Mr. Lee holds a Juris Doctor from the American University Washington College of Law and a BA in Economics from the State University of New York. He is an Attorney at Law in the United States and a Solicitor of Law in Hong Kong SAR. New Asia Partners was founded in 2002 by Dennis Nguyen and Shu Fan Lee as a private equity group dedicated to bringing global expertise and local knowledge to leading companies in the health sciences, consumer / retail and energy / environmental sectors

Florence is an Investment Director with ATP Capital Pte Ltd, a Singapore based Asian focus biotech fund with a global footprint. Florence started her career in the finance industry, then switched over to the pharmaceutical industry joining Roche Singapore as a Sales Executive and progressed to taking on sales and product management position within one year of joining. Florence joined ATP Capital after four years as General Manager of sanofi-aventis Singapore Pte Ltd. In sanofi-aventis, Florence was responsible for organizational restructuring, operational efficiency, strategic development to strengthen market presence and profitability of the newly merged company. Prior to sanofi-aventis Florence spent ten years in various senior management position in GSK Singapore and in GSK’s UK Head Office.

Nisa Leung is a Partner of Qiming Ventures specializing in health care investments. Prior to joining Qiming, she was co-founder of Biomedic Holdings with operations and investments in medical devices, pharmaceuticals and health care services in China including most recently a founding investment into Novamed Pharmaceuticals Inc (Shanghai), a specialty pharmaceutical company focused on oncology and CNS. Nisa was Venture Partner of PacRim Ventures in Menlo Park, and was previously with Softbank/Mobius Venture Capital. Nisa currently sits on the board of Biomedic Holdings (Shanghai) and related companies, Cardiva Medical (Mountain View CA) and American Cancer Centers (Shanghai). Nisa earned her MBA from Stanford Graduate School of Business and a BS from Cornell University. She is member of Cornell University Council and the only non-US member of Cornell Life Sciences Advisory Board.

Dr. James Li joined Kleiner Perkins Caufield & Byers in October 2006. Prior to joining KPCB, James spent over 15 years of outstanding service with Merck Co. where he held positions of increasing responsibility in basic research, clinical research, regulatory affairs, new product development/access and franchise management, all with an Asia Pacific focus. James has been a known expert in the Asia Pacific pharmaceutical industry. He has published a number of papers on the region’s clinical, regulatory access and marketing issues and has been a regular speaker and guest consultant for a number of government regulatory agencies, academic institutes and industry associations. From 1996 to 2000, James was the Medical Director of Merck’s China Operations, where he successfully developed a first class professional medical team, conducted early phase clinical studies, and developed strong relationships with government regulatory agencies, key opinion leaders, and top research institutes. In 2003, James was appointed Regional Marketing Director, Hypertension, for the Asia Region and successfully drove the fast growth of Merck’s largest franchise in the region. James received his Medical Degree from Shanghai Medical University, completing an internship in Internal Medicine and a rotation in Oncology, followed by a Master of Science degree in Microbiology from the University of Montana.

Svend Licht joined Novo in 1986 working with economy and production planning activities in the Bio-chemicals Division. From there he moved on as manager for the planning function of International Op-erations for the enzyme business in Novo Nordisk, building up the international planning systems and procedures for the industrial enzyme organisation. In 1994 he went to Paris as sales support director for the European enzyme business and in 1999 he took over the position as sales director and general manager for Middle East & Africa based out of Greece. He returned to Denmark in 2001 as senior director in the newly established Biotech Business Devel-opment group in Novozymes. This group was established to be an incubator for new business ideas for Novozymes developed through internal R&D projects, corporate partnering and acquisition activi-ties. His current role includes strategy development as well as general business development activities within commecialisation of technologies and solutions to the biopharmaceutical industry. In his recent positions he has been responsible for the completion of several international acquisitions and the management of numerous other deal processes. Prior to joining Novo, he worked as a chemical plant process engineer at Haldor Topsøe, Denmark (1985-1986). He holds a BSc in chemical engineering from the technical university in Copenhagen, a BSc in foreign trade from Copenhagen Business School and an executive MBA with distinction from Ashridge Management College in UK. He is Novozymes representative in Corporate Strategy Board (an international forum for sharing of better practises). Svend is a speaker on conferences on the topics of a.o. strategy, acquisition and industrial biotechnology. He is the chairman of board for Wiseled - a Danish start-up company active development and com-mercialisation of innovative professional flashlights (www.wiseled.com). Further to this he is also on the board of Unisensor (www.unisensor.dk) a danish company specialising in optical analysis in the medical, veterinary and biotechnological segments.

Dr. Edison Liu was educated at Stanford University receiving a Bachelors of Science in Chemistry and Psychology (1973) and an M.D. in 1978. He received his residency training in internal medicine at Washington University, St. Louis, and clinical cancer fellowships at Stanford University (Oncology), and at the University of California at San Francisco (Hematology). He then pursued post-doctoral studies as a Damon-Runyan Cancer Research Fellow at the University of California at San Francisco in the laboratory of Dr. J. Michael Bishop. In 1987, he joined the faculty of Medicine at the University of North Carolina at Chapel Hill where he was director of UNC's Specialized Program of Research Excellence (SPORE) in Breast Cancer. In 1996, he joined the NCI as the Director of the Division of Clinical Sciences responsible for the intramural clinical and translational programmes at the NCI that comprised 1200 employees and over 100 principal investigators. In 2001, Dr. Liu assumed the position of Executive Director, Genome Institute of Singapore. He founded the institute which now houses 280 scientists within Singapore’s Biopolis. His current scientific research investigates the dynamics of gene regulation on a genome scale that can explain biological states in cancer. Dr. Liu has contributed over 250 articles, reviews, books, and book chapters to the scientific literature. Dr. Liu also was the executive director of the Singapore Cancer Syndicate, a governmental funding agency supporting clinical translational cancer research (2003-2008), and is currently the Executive Director of the Singapore Tissue Network, the national tissue repository in Singapore. He is the Chairman of the Governing Board for Singapore’s Health Sciences Authority which is the key health regulatory agency for the nation that includes the FDA and national blood banking equivalents. In 2007, Dr. Liu was elected as President of the Human Genome Organization (HUGO). Dr. Liu’s awards include the Leukemia Society Scholar (1991-1996), the Brinker International Award for basic science research in Breast Cancer (1996), the Rosenthal Award from the American Association for Cancer Research (2000), the President’s Public Service Medal for his work in helping Singapore resolve the SARS crisis, and a Doctor of Medicine Sciences honoris causa (Queen’s University, Belfast. 2007). Dr. Liu’s current scientific interests are the functional genomics of breast cancer that spans from basic to epidemiologic studies. He writes general commentaries for the Singapore’s national newspaper, The Straits Times and for the biotechnology magazine, BioSpectrum.

Liu Yuwen, holds Ms in Pharmaceutics from China Pharmaceutical University and Master of management at Fudan University, China and Norwegian Management School, and is a licensed pharmacist. She started her career with Capsugel® , a division of Pfizer in Suzhou, China as a quality engineer in 1997 and was promoted to be QA manager in April 1998. In May 2000, following strategic expansion of Capsugel China, she transferred to New Business Development department managing new product market opportunity exploration in great China region. In May 2003, she moved to Shanghai as General Manager to set up the representative office for Perrigo Company (the world’s largest manufacturer of OTC pharmaceutical and nutritional products for the store brand market) and is taking charge of all related market development activities including JV’s in China as well as supply management in other Asia Pacific regions such as Japan, Korea, Taiwan etc. In Dec. 2005, she moved back to Suzhou as executive vice president for BioBay, a bio science park funded by Suzhou Industrial Park, whose mission is to build an integrated comprehensive platform for biotech, pharmaceutical and nanotech research and development in China. August, 2007, she became the General Manager of BioBay and Vice President of Suzhou Ventures Group.

Ms Ma has been an advisor to TVM Capital since late 2004 and joined TVM Capital as Venture Partner for life sciences in 2007. She entered the life sciences industry in 2000 when she was a Senior Vice President at Vertex Management, where she co-led the Global Biotechnology Investment Division. Since 2003, she has been advising life sciences businesses wishing to expand or raise funds in Asia. Prior to 2000, she accumulated over 16 years of international investment, corporate finance and general management experience with Singapore Technologies, Banque Nationale de Paris, General Electric (USA), Morgan Grenfell, Booz, Allen & Hamilton and Price Waterhouse. Ms Ma holds a MSc in Biotechnology from the Johns Hopkins University, USA, a MBA from Manchester Business School, UK and a Bachelor of Accountancy from the National University of Singapore.

Dr. Macaraeg earned his medical degree from the University of the Philippines and completed his internship at the Philippine General Hospital. He did general practice for a couple of years before joining the industry. Currently he is the Regional (Asia-Pacific) Disease Area Head for Immunology at Bristol-Myers Squibb. He has served as a lecturer at the University of the Philippines College of Allied Medical Professions. His interests include healthcare and pharmaceutical policy, medical-marketing promotional strategies, and research and development trends.

John Machulski is currently Senior Project Director at Lonza Biologics Singapore Pte Ltd. Lonza is a Swiss based custom manufacturing company which specializes in contract development and manufacturing services for the pharmaceutical and biotech industries. In this role, John has engineering, construction and startup responsibility for Lonza’s $600MioUSD capital investment program for their two planned production facilities at Tuas. John has been with Lonza for 8+ years and served in several project and operational functions in their US operations prior to coming to Singapore in 2007. Prior to joining Lonza, he was with Wyeth Pharmaceuticals and Johnson & Johnson in a variety of engineering and operations roles. John holds a BS in Mechanical Engineering from Lehigh University and an MBA from LaSalle University, both in the US.

Dr. Martin is President and CEO of Takeda Research Investment, Inc (TRI), the corporate venture arm of Takeda Pharmaceutical Company, Ltd. TRI was established in Palo Alto, California in November 2001 with US$100MM of committed capital for early stage strategic investments. Dr Martin joined TRI in 2003, and has been responsible for building a portfolio of strategic investments representing about US$30MM under management. During more than 30 years R&D experience in large Pharma (Wellcome, UK; Glaxo Wellcome, UK: Hoffman La Roche, USA) and Biotech (Telik, USA), Dr Martin was responsible for three IND submissions and jointly led the preclinical development of Zomig® now marketed worldwide for the acute treatment of migraine. Prior to joining Takeda, Dr Martin established the California Bay Area biopharmaceutical consulting firm Discovery-Insight. He received his Bachelor of Science degree in Pharmacology from the University of Bath, UK and his doctorate from University College, London, UK.

Mr. Mashaal has more than 30 years' experience in the pharmaceutical industry. He started his career with Syntex Laboratories Ltd., (now Roche Bioscience Inc.) in Canada and continued with Syntex International S.A. where he was responsible for the management of systemic steroid products. In 1973, Mr. Mashaal joined the 3M Company and was given responsibility for assisting in the creation of a clinical research group and managing the clinical research development of new molecules in the field of non-steroidal anti-inflammatory (NSAID) analgesic and cardiovascular products. In 1975, Mr. Mashaal was given responsibility for international business development in the health and sciences sector at 3M. In 1980, Mr. Mashaal founded Mashaal Enterprises Ltd, a holding company with interests in healthcare and biotechnology-related companies, for the investment in and development of emerging companies in the fields of health and sciences. In 1987, Mr. Mashaal founded SciTech Medical for the international market development of pharmaceuticals, medical devices and diagnostics. Mr. Mashaal is Chairman of both Mashaal Enterprises Limited and SciTech Medical. In 1988 Mr. Mashaal founded SciTech Genetics to develop, manufacture and market biotechnology-derived products, first in the Asia Pacific region and later in the markets of Europe and the Americas. In 1999, when Sonic made a substantial equity investment, SciTech Genetics underwent a name change to SciGen Pte Limited and Mr. Mashaal remained as the Chief Executive Officer. In 2003 Mr. Mashaal relinquished his position as the CEO and was given the position of Executive Vice Chairman. In 2005, after Bioton became the majority shareholder Mr. Mashaal was asked to resume his position of CEO and in addition was appointed Chairman.

Kiran Mazumdar-Shaw's pioneering efforts in biotechnology have drawn global recognition both for Indian Industry and Biocon. Her unique vision has steered Biocon's transition from an industrial enzymes company to an integrated biopharmaceutical company with strategic research initiatives. Biocon is today recognised as India's pioneering biotech enterprise. As Chairperson and Mission Leader of CII's National Task Force on Biotechnology she has led several delegations to USA, Canada, UK, etc. to propel India into the global super league of biotech trailblazers. She chairs Karnataka's Vision Group on Biotechnology and has served on the Board of Science Foundation, Ireland. She also serves on the Advisory Council of the Government’s Department of Biotechnology where she has been instrumental in bringing government, industry and academia together, to chart a clear and progressive growth path for Biotechnology in India. Most recently, Kiran has been invited to join the Prime Minister’s Council on Trade & Industry. Kiran is the recipient of several prestigious awards including the ET Businesswoman of the Year, Best Woman Entrepreneur, Model Employer, Ernst & Young's Entrepreneur of the Year Award for Life Sciences & Healthcare, Leading Exporter, Outstanding Citizen, Technology Pioneer, etc. Her most cherished awards however are two of India’s highest civilian honours - the PADMASHRI (1989) presented to her by the erstwhile President of India, for her pioneering efforts in Industrial Biotechnology and the PADMABHUSHAN (2005) received from the President of India, Dr. APJ Abdul Kalam. A successful technocrat of global standing, Kiran is highly respected in the corporate world. She is a much sought after biotech pioneer who has been referred to as "India's Biotech Queen" by The Economist and "India's mother of invention" by New York Times. Kiran received a graduate honours degree in Zoology from Bangalore University (1973) and qualified as a Master Brewer from Ballarat University, Australia (1975). Kiran also received an honorary Doctorate of Science, from her alma mater, Ballarat University, in recognition of her pre-eminent contributions to the field of Biotechnology. In addition she has received honorary doctorates from IIT, Roorkee, the Manipal Academy of Higher Education (MAHE) and the University of Abertay Dundee. She is married to John Shaw, a Scotsman and Indophile, who headed a leading textiles MNC, Madura Coats from 1991-1998 as Chairman and Managing Director. John Shaw is currently the Vice-Chairman, Biocon Limited

Chirag joined Morgan Stanley’s Detroit team in 1999 and spent 7 years in the company reaching the position of Head of Mergers and Acquisitions and Strategy at the company’s Chicago Office. During his career at Morgan Stanley, he has advised his clients on a range of corporate strategy matters, which includes financial restructuring, corporate brand image, takeover and mergers, new market forays, before going full time into mergers and acquisitions. He was an active part of the strategic team responsible for merger/buyouts of HP/Compaq, Chrysler/Daimler, AOL/Time Warner and many more. In the year 2006 he moved to India and joined Intas Biopharmaceuticals Ltd. Currently, he is the in charge of Strategic Planning and Development at Intas Biopharmaceuticals. His job includes long term strategic planning, corporate structure, corporate diversification, business development. He was actively involved in the acquisition of BPD Inc in the United States. He has been one of the key members of the corporate team involved in getting two private equity investors in invest in the company over the past three years. Mr Mehta has a Bachelors degree in Physics from Gujarat University India and Masters in Business Administration (Honors) from University of Michigan.

Sriram Nadathur currently serves as a Director of Nadathur Holdings & Investments Pvt, Ltd. (India), a private investment group started by N.S. Raghavan (Co-founder of Infosys Technologies NASDAQ - INFY). His primary responsibilities include building and managing the firm’s investments in the Healthcare and Life Sciences segments. He also serves as a Director of Nadathur Fareast Pte, Ltd. (Singapore) a company focused on international investments, and aiding expansion plans of existing portfolio companies using Singapore as a hub. Prior to this, Sriram was part of the founding team and Vice President Operations of Syndicated Research Group (USA), a Finance and HR advisory services company catering to CFOs and Heads of HR of F500 clients. He also was part of the founding team of start-up World Research Advisory (USA), an advisory services firm catering to Treasurers of F500 companies. Sriram holds a Bachelors degree in Industrial Engineering from R.V. College of Engineering, Bangalore, and an MBA from Northeastern University, Boston.

Sarath has been focused on venture capital/private equity in India for more than ten years, investing in rapidly growing businesses across tech, biotech, and manufacturing sectors. He is the Managing Partner of VenturEast Funds which has over $300 million under management. VenturEast has consistently raised funds with a pioneering investment focus. Prior to this, Sarath built a trading and manufacturing business spanning the USA and India. He also gained significant experience working for Procter & Gamble in the area of brand management (marketing & general management) in the USA, and in manufacturing with British American Tobacco subsidiary (VST Industries). His academic qualification includes a Bachelor of Technology (B.Tech.) from IIT, Madras and MBA (Finance) from University of Chicago. Sarath has been actively supporting technology development and venture capital with active involvement in various industry organizations. He has been a past-secretary of the Indian Venture Capital Association, and is a member of the Investment Committees of UTI Ventures funds (Subsidiary of India’s largest Mutual Fund Manager) and previously of Avigo Ventures Dubai (sponsored by the Lord Bagri group of the UK). He is the Chairman of the Agri-Business Incubator at ICRISAT, Hyderabad, (elected the best incubator in India in 2006), and is a member of the Governing Board of ICICI Knowledge Park Incubator. He is the treasurer of Association for Biotech Lead Enterprises (ABLE) and is an Executive Committee member of the PanIIT Association.

W. Carter Neild, CFA, is a General Partner of OrbiMed, a $5 billion healthcare-focused investment firm with offices in New York, Shanghai and Mumbai. OrbiMed recently launched a healthcare venture capital fund dedicated to the Asia/Pacific region. Mr. Neild was previously a Divisional Director in the UBS Alternative Investments Group, active across private equity, venture capital and hedge fund strategies. Mr. Neild received an M.B.A. in Finance from the University of Chicago, a B.A. in Economics from Emory University, and a C.E.P. from the Institute D'Etudes Politiques in Paris. He received the CFA charter in 1995.

Prior to joining INVIDA as the Chief Financial Officer, David was Group CFO of The Global Brands Group, an Intellectual Property trading group based in Singapore. Previously he has had stints as Regional CFO for MTV Networks Asia covering the Asia Pacific region and the EMEA region for Mediaedge:cia, a part of WPP Group. He has also worked at Bankers Trust in Regional business development roles in Asia after his qualification as a Chartered Accountant. He is a Member of the Institute of Chartered Accountants of Australia and holds an MBA and an MEc from Macquarie University, Australia and a BEc from the University of Sydney, Australia.

Fredrik Nyberg is General Partner at BioVeda Capital (Singapore), a life science venture capital fund investing in emerging technologies. He is also the co-founder and Managing Partner of Biomedical Strategy Consultants Pte Ltd, a strategic and investment advisory firm serving the global medical devices, diagnostics, pharmaceutical and biotechnology industries with particular focus on opportunities in Asia-Pacific. Fredrik has 24 years experience in the healthcare industry from senior sales, marketing and general management positions. He has lived and worked in Asia since 1990. Fredrik has held prior positions as Group General Manager and as Marketing Director for major healthcare companies based in Singapore, Malaysia and Japan. He has also held senior European-based marketing positions with particular focus on anaesthesiology, interventional cardiology and critical care. Fredrik is a member of several professional associations including the Medical Marketing Association (U.S.) and the Institute of Management Consultants (Singapore). Fredrik holds a BSc from Gothenburg University, Sweden, and an MBA from Henley Management College, UK.

Mr Ong Chong Jin joined the Singapore Exchange (SGX) as Senior Vice President and Head, Catalist on 8 July 2008. He is responsible for growing and developing Catalist as a choice capital platform in Asia catered for fast growing companies. Mr Ong joined SGX from CLSA Merchant Bankers where he was Managing Director and Head of Investment Banking for Singapore and Malaysia. He was responsible for growing the firm’s investment banking franchise in the two countries. Prior to CLSA Merchant Bankers, he held senior positions in Cazenove & Co. in Singapore and Merrill Lynch in Hong Kong. Mr Ong started his banking career with Citibank N.A. Mr Ong holds a Masters’ in Business Administration (MBA) from the J.L. Kellogg Graduate School of Management, Northwestern University, USA, and also a Bachelor’s degree in Business Administration (BBA) from the National University of Singapore. He is also a certified Chartered Financial Analyst (CFA).

Michelle Peake has been working in the field of biotechnology since 1994, after graduating with a BSc with Japanese from Griffith University, Australia. She joined Agen as a manufacturing technician working on their D-DIMER product, and then moved to development where she was promoted to Lead Scientist on the company's FIV test. Michelle moved for personal reasons to England in 1996, whereby she joined Cantab Pharmaceuticals as a cGMP manufacturing scientist based on her experience in column chromatography. She continued to work closely with the process development group which led to her moving to this department after 2 years. She gained extensive experience in protein purification and also analytical assays. In 2000 due to a merger with Xenova Research, Michelle moved back to cGMP manufacture where she was promoted to Manufacturing Supervisor, in charge of the day-to-day running of the clinical trials manufacturing facility. In December 2003 Michelle was appointed as the Director of Manufacturing for Alpha Biologics and has since been based in Penang, Malaysia – she has since been promoted to Chief Operating Officer. Michelle's areas of expertise include cGMP manufacture, protein purification and fill/finish.

Mr. Scott has helped launch over thirty life science startups in the U.S. and China as a founder, investor and advisor. He founded the ChinaBio® Accelerator to help fund and mentor early stage life science companies in China, and serves as the managing principal for ChinaBio® Consulting, providing research services to pharma and biotech companies with business in China. Mr. Scott is also the president and co-founder of Life Science Angels, an angel investment group that has funded 26 biotechnology and medical device companies since 2005, and executive editor of ChinaBio® Today. He previously held senior executive positions at Price Waterhouse, Capgemini and MCI, and was co-founder of a 200-person consulting firm. Mr. Scott attended University of Missouri, where he studied mathematics, microbiology and computer science.

Dr. Victor Shi is Asia President of QIAGEN, a publicly-listed leading provider of sample and assay technologies in the field of molecular diagnostics. Dr. Shi heads QIAGEN’s commercial operations and strategic development in Asia and manages an organization with around 400 employees in 8 subsidiaries. He has over 17 years’ experience in life science business development, management and investment. Previously held positions include Managing Partner, Aura Partners (Shanghai and Hong Kong), Senior Vice President, Corporate Development, Bridge Pharmaceuticals (Menlo Park, California), Managing Director of Discovery Resources Group (Palo Alto, California), Vice President of Corporate Development at Genospectra (Fremont, California), and Director of Asia Operations at A. M. Pappas & Associates (Singapore). He was also a faculty member at National University of Singapore School of Medicine and a cancer research scientist at Merck & Co. Dr. Shi holds Ph.D. and M.S. degrees from the University of Rochester, New York, and a B.S. degree from the University of Science and Technology of China.

Dr. Yufang Shi is a Professor in the Department of Molecular Genetics, Microbiology and Immunology at Robert Wood Johnson Medical School. He was recently appointed as the Director of the Institute of Health Sciences of Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences and Shanghai Jiao Tong University School of Medicine. He received a veterinary degree from Shandong Agricultural University, China and a M.Sc. in Immunoparasitology and a Ph.D. in Immunology from the University of Alberta, Edmonton, Canada. His postdoctoral training was in Immunology at the University of Toronto, Canada. Since 1988, Dr. Shi has been studying apoptosis and immune regulation. His research on activation-induced cell death (AICD), role of c-myc in apoptosis, opioid and stress-induced lymphocyte apoptosis, mTOR inhibitor and cancer therapy, CD4+ T cells and asthma, granzyme B and Th2 AICD, and MHCIb CD8+ T cells and autoimmunity were publish in Nature, Science, Nature Medicine, Immunity, Cell Stem Cell, PNAS, Cancer Research, Journal of Immunology and Journal of Experimental Medicine. His current research is focused on the molecular mechanisms of mesenchymal stem cell-mediated immunosuppression and clinical applications. Dr. Shi was an Associate Editor of the Journal of Immunology and is currently an Editor of Cell Research.

Dr. Ming Shu serves as a Principal at Henderson Equity Partners (HEP), which currently manages approximately US$ 3 billion of capital. At HEP, Ming leads the team's investment in the Greater China region, and is based in the Hong Kong Office. HEP is the private equity investment arm of Henderson Global Investors (HGI), a leading global asset management firm with over US$ 120 billion under management. A native of Beijing, Ming received his Ph.D. in Biomedical Engineering at Duke University and his MBA at Harvard Business School.

Rajiv Shukla joined ICICI Venture in 2008 and focuses on investments in the Lifescience and Chemicals sectors. Rajiv has senior leadership experience across corporate development, investment banking and management consulting. He was previously Executive Director and Global Head of the Lifescience and Chemicals practice at Avendus Capital, a top 5 investment bank in India. Before that, he was Senior Director of Business Development at Pfizer at their global headquarters. At Pfizer, Rajiv played a key role in five acquisitions totaling USD 63 billion besides leading numerous growth and cost management initiatives for which he received several leadership awards. Rajiv began his career as a Management Consultant at the Boston Consulting Group. He serves on the CII National Committee on Pharmaceuticals and the Bombay Chamber of Commerce and Industry IPR Committee. Rajiv has a Master’s degree in Healthcare Management from Harvard University, a Fellowship in Pharmaceutics from the State University of New York and a Bachelor’s degree in Pharmaceutics from the Institute of Technology at Banaras Hindu University.

Roberto Silveira joined Pfizer in 1989 in Brazil working as Production Manager in the Fermentation plant. In 1994, Roberto moved to Pfizer Headquarter in New York and held global positions of increasing responsibilities in Pfizer Global Manufacturing. In 2003, Roberto was appointed to his current position as Sr. Director/Team Leader of Bioprocess Support, and is responsible for the optimization and technical support for marketed bio-processes products. Roberto also defines sourcing strategies for all biological products within the Pfizer portfolio, and manages technology transfers for new biological candidates at the manufacturing sites. Roberto earned a B.Sc. in Chemical Engineering from Sáo Paulo University in Brazil, and a Ph.D. in Fermentation Technology from Hiroshima University in Japan.

Dr Lalji Singh, presently the Director of the Centre for Cellular & Molecular Biology (CSIR), Hyderabad, born on 5th July 1947; obtained his M.Sc and Ph.D. from Banaras Hindu University, Varanasi; Postdoctoral Fellow with Commonwealth Fellowship and Research Associate at Edinburgh Univ. (UK); Visiting Fellow at National Univ., Australia; Visiting Scientist at Edinburgh University (UK); more than 175 research publications in reputed International and National Journals; joined CCMB in 1987 and became Director in 1998; Dr. Lalji Singh has won several awards in his career including Padma Shri, J C Bose Fellowship, FICCI Award in Life Sciences, Goyal Prize in Life Sciences, Shri Om Prakash Bhasin Award for Biotechnology, VASVIK Award for Biological Sciences & Technology, Prof. Vishwanath Memorial Lecture Award, J C Bose Award for Research in Life Sciences, Ranbaxy Research Award for Basic Medical Sciences, CSIR Technology Award for Biological Sciences, INSA Young Scientists Medal. Fellow of the Indian Academy of Sciences, National Academy of Sciences, Indian National Science Academy, Andhra Pradesh Akademi of Sciences, National Academy of Agricultural Sciences, National Academy of Medical Sciences, and Third World Academy of Sciences.

Kanwarjit “KJ” Singh is a physician who has worked as a clinician and as an executive in the Life Sciences and Pharma/Biotech sectors. He has worked as a consultant at McKinsey and Company and at Glaxo, Amgen and Bayer in the commercial, product development, planning and business development areas. More recently he has directed his professional energies to the field of global health and is currently a Senior Program Officer at the Bill and Melinda Gates Foundation. He has a special focus on the development and delivery of innovative new vaccines and on strategies to develop cost effective clinical trial, regulatory and manufacturing approaches adapted to the needs of emerging economies. Dr Singh received his initial education at St Stephen's College, Delhi (BS Physics Honors, National Science Talent Scholar) and Oxford University (MA, M Phil Economics). He subsequently received an MBA from the Sloan School at MIT and an MD from Columbia University. He is a Diplomat of the American Board of Internal Medicine. He has an avid interest in both scientific innovation and in policy issues relating to the delivery of effective medical and public health solutions in a cost effective manner. He is active in a variety of industry and professional bodies. He sits on the Boards of the International Biomedical Research Alliance and RaPID and the World Affairs Council in Seattle. He is also an affiliate Assistant Professor at the University of Washington.

Thibaud Stoll is Head Global Biopharmaceutical Operations at Novartis. In this function, he manages 6 large-scale facilities around the world, which are in charge of late-stage technical development, clinical and commercial manufacturing of biopharmaceutical and biosimilar active ingredients, using both cell culture and microbial fermentation technologies. Dr Stoll joined Novartis in 2000 to participate to the start-up of a new large-scale cell-culture facility in Huningue (F), from construction to FDA approval. He became then the Site Head of this facility. In this function, he was responsible for the worldwide manufacturing of Xolair®. Prior to joining Novartis, Thibaud held positions in biotechnology technical development at Genentech, Inc., in California, and in chemical production at Firmenich SA, in Switzerland. Thibaud Stoll has a Master’s Degree in Chemical Engineering from the Massachusetts Institute of Technology (MIT) and a PhD in Biotechnology from the Swiss Federal Institute of Technology (EPFL) in Lausanne.

Ling Su is currently Vice President, Clinical Research and Development for the Asia Pacific region in Wyeth, based in Shanghai, China. He has nearly 20 years of experience in the pharmaceutical industry and the regulatory agency, in both US and Asia, and in a variety of therapeutic/disease areas. He started his career working in the Bureau of Drugs, Ministry of Health, from 1986-1990. He was a Visiting Scientist in the Center for Drug Evaluation and Research, US FDA, in 1992-1993. He joined Merck Research Laboratories (MRL), Merck & Co., in 1996 as an Epidemiologist, responsible for design and conduct of epidemiological and outcomes research projects to support drug and vaccine development programs. In 2000, he was appointed Medical Director for Merck Sharp & Dohme (China) based in Hong Kong, where he managed the Medical Department and was responsible for regulatory affairs and product registration, clinical research, medical services, new product planning, and pharmacovigilance for Merck’s subsidiary in China. In 2003 he returned to MRL and assumed the position of Senior Director, Global Strategic Regulatory Development, supporting vaccine regulatory strategic development and Japan regulatory activities. Prior to joining Wyeth, he was International Pharma Development Director and subsequently, Medical and Pharma Development Director at Shanghai Roche Pharmaceuticals Ltd from 2004-2007. In this position, he was responsible for global developmental clinical trials and local clinical studies, clinical trial regulatory approval, drug safety, and medical marketing in China and Hong Kong. Ling Su received his BS degree in clinical pharmacology from Shanghai Medical University, China; and MS degree in clinical pharmacy and drug development and PhD in epidemiology, both from the University of North Carolina at Chapel Hill, USA. He is an adjunct professor in the School of Pharmacy, Fudan University.

Dr Tabiin is the Vice President of the Biomedical Sciences Division at Exploit Technologies Pte Ltd (ETPL), the commercialization arm of the Agency for Science, Technology and Research (A*STAR) in Singapore. ETPL is a technology transfer office that facilitates the transfer of leading-edge technologies from the 14 national research institutes under A*STAR to industry. Dr Tabiin leads the team that is responsible for the commercialization of the Biomedical technologies. ETPL also provides other technology management services such as intellectual property filing and management, technology and competitive intelligence, managing incubation and spin-off companies, and providing legal advice to A*STAR research institutes. Prior to joining ETPL, Dr Tabiin had a balanced career spanning 15 years in academia as well as in the industry. He held research and development positions at Harvard Medical School and Johns Hopkins Singapore as well as product development positions at Genelabs and Merck.

Donald Tan is the Director of the Singapore National Eye Centre, Chairman of the Singapore Eye Research Institute, and the Head of the Dept of Ophthalmology, Yong Loo Lin School of Medicine, at the National University of Singapore. As a clinician scientist in the field of cornea and stem cell research, his clinical and translational research interests lie in corneal transplantation, ocular surface stem cell biology and transplantation, pterygium surgery, corneal refractive surgery, femtosecond laser-assisted surgery and tissue engineering in development of the artificial cornea. His other research interests include ocular drug delivery systems, epidemiology of myopia, visual psychophysics, and interventional myopia treatments. Professor Tan has published 188 scientific peer-reviewed articles to date, and has written 16 book chapters on his field. Professor Tan has been awarded numerous regional and international awards, and in 2006, was awarded the first Minister for Health Award For Outstanding Performance In Public Health in Singapore for leading the Singapore team, which first identified the cause of the global outbreak of Fusarium Keratitis. He currently heads a major NRF Translational Clinical Research (TCR) grant focusing on development of new wound healing approaches in ocular surgery.

Dr. Patrick Tan holds a joint appointment as an Associate Professor at the Duke-NUS Graduate Medical School and a Group Leader at the Genome Institute of Singapore. He is the Program Leader in Genomic Oncology within the Singapore Cancer Research Centre of Excellence, a recently announced S$170M research initiative for basic and translational cancer research. His research interests lie in the application of genomics to address biomedical questions in cancer and infectious disease. He received his B.A. (summa cum laude) from Harvard University and MD PhD degree from Stanford University, where he received the Charles Yanofsky prize for Most Outstanding Graduate Thesis in Physics, Biology or Chemistry. Locally, he has received the President’s Scholarship, Loke Cheng Kim foundation scholarship, Young Scientist Award (A-STAR), Singapore Youth Award (twice), and the Singhealth Investigator Excellence Award. He is an editorial board member of the journals SGH Proceedings and Cancer Research. He is a member of the Local Review Panel (LRP) to the National Medical Research Council and Biomedical Research Council, a member of Specialists Accreditation Board, Translational Medicine, and Bioethics Advisory Committee (BAC), a national body that provides advice to the Singapore government on ethical issues related to biomedical research. Dr Tan led an international team of researchers in groundbreaking work to establish a comprehensive molecular map of stomach cancer, providing significant findings on the biological pathways involved.

Masaru TANIGUCHI received his M.D. and Ph.D. degrees at Chiba University School of Medicine (1974). He belonged to Chiba University as a research associate (1974-1979). He did postdoctoral work at the Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia (1976-1977). He was appointed to be a Professor of Immunology there (1980-2004). He served as a Dean of Chiba University School of Medicine (1996-2000). He was also a President of Japanese Society for Immunology (1997 to 1998). He was then appointed to be a founding Director at the RIKEN RCAI in 2001(-present). The NKT cell that he identified in 1986 is known as an important lymphocyte that bridges the innate and acquired systems (Taniguchi et al. Annual Review Immunol 2003). He was awarded Hideyo Noguchi Memorial Medical Prize in 1993, Uehara Prize in 2004, and the Medal with Purple Ribbon from the Emperor in 2004.

Dr Anand Tharmaratnam graduated in medicine from University College London, UK in 1992, he specialised in anesthesia and is a member of the Royal College of Anesthetists, UK. He joined Quintiles in April 1997 as a clinical pharmacologist at Guys Drug Research Unit, having spent the last 5 years working in anesthesiology and critical care medicine in London. He was a Medical Director in Quintiles Europe from 1999 to 2001, following when he set up the first global ECG lab outside Europe and the US, in Mumbai in India in 2002, QECG. In 2003 he joined Quintiles Japan and helped set up Quintiles Japan international businesses in Hawaii, Brazil and Peru. In August 2004 he moved to Singapore as CEO of Quintiles SE Asia, Taiwan and Korea based in Singapore and in 2006 took responsibility for the Quintiles business in Asia Pacific. This is today the largest clinical research organization in the region and it represents the single largest clinical development employer in Asia.

Christophe Tournerie has 15 years’ experience in clinical research in Europe and Asia, including Japan, working with pharmaceutical companies and clinical research organisations After completion of medical studies in Paris and various hospital assignments in France, spent a period of 3 years at the National Research Institute in France in the field of drug development in anti-HIV products. Introduction to the pharmaceutical industry was as Medical Director in an American biotechnology company. Subsequently moved to PAREXEL, which included an assignment as Director of Project Management for Southern Europe and as Senior Director of Japanese Operations in Japan. More recently held the position of Regional Clinical Research Director, South East Asia, and Regional Director and Head of the South East Asia Research Unit for Sanofi-Aventis, based in Singapore. At PharmaNet, Dr. Tournerie is responsible for the management of operations in Asia Pacific.

Steven Tregay is the founder, President and CEO of Forma Therapeutics, a global integrated drug discovery company. Previously, he was the Managing Director for the $200M Novartis Option Fund. He has lead the fund’s investments in Forma Therapeutics, Adenosine Therapeutics (Sold; CLDA) and Cequent Pharmaceuticals. Prior to joining the venture group, he was the Executive Director and Head of Strategic Alliances-Oncology, Ophthalmology and Technologies at the Novartis Institutes for BioMedical Research. He managed a team of ten who were responsible for identification, negotiation and management of collaborations for the Oncology and Ophthalmology disease areas and the Technology areas. Prior to Novartis, he had roles in business development and research. He received his Ph.D. and M.S. in organic chemistry from Harvard University and a B.S. from Davidson College.

Prior to joining TPG as Operating Partner in 2007, Mr. Tsang was with the Australian Capital Equity (ACE) since 2000 both in the London and Beijing office. He was the Managing Director of China who oversees the group’s investment activities in the region. During his time at ACE, he also served as the Managing Director of the WesTrac China dealership. Mr. Tsang led the growth of this business from a start-up stage through to profitable growth with present staff of about 1,000. Under his leadership, WesTrac China received the Australian Chamber of Commerce’s Business Excellence Award in the Greater China region and the company was also recognized as having The Best Volunteer Group by China Communist Youth League. Mr. Tsang also served as Chairman of the Caterpillar China Dealers’ Association. Before joining ACE, Mr. Tsang worked for The Walt Disney Company from 1994 to 2000. During that time, he was the Director of Business Planning and Development of Asia-Pacific for Walt Disney Imagineering, the theme park and real estate division of Disney, where he initiated and shepherded the Hong Kong Disneyland deal to its completion. Prior to his time at Disney, Mr. Tsang worked at The Boston Consulting Group in Asia-Pacific and at Citibank in the U.S. Mr. Tsang holds an MBA in Management and Marketing from Northwestern University, and a BS in Operations Research & Industrial Engineering from Cornell University. Mr. Tsang is an active member of the China Venture Capital Association, including numerous advisory and board roles in start-ups, and also served as an honorary member of the Board of Governors of Beijing Volunteer Association.

Masanori Tsuno currently serves as President of Eisai Global Clinical Development, Eisai’s global clinical research network, as well as President of Eisai Medical Research, Inc. (USA) and Vice President of Eisai Co., Ltd. (Japan). Masanori joined Eisai’s research laboratories in 1979. Since that time, he has held positions of increasing responsibility starting with his move in 1988 to London as Director of International Research Coordination to establish Eisai Europe Ltd., a newly incorporated clinical research company of Eisai in the EU. After five years in London, Masanori continued his development in the US as a Project Manager of a new drug product plant and formulation research facility in Research Triangle Park (US), Head of International Development Planning (Japan), Director of R&D Portfolio Planning (Japan) and Global Project Leaders of E5564, a new drug for the treatment of severe Sepsis, Head of Clinical Development Europe, and VP of Global Project Management, Eisai R&D Management Co. Ltd. (Japan). Masanori has a Master’s degree in chemistry from the graduate school at Tokyo University of Agriculture and Technology.

Suri Venkatachalam is the founder and currently serves as the CEO of Connexios. Connexios is a healthcare products company that leverages a unique translational network biology approach to disease biology to discover and develop novel therapeutics and diagnostics for unmet clinical needs in the area of chronic disease. Its wholly owned subsidiary, Inexios, undertakes marketing of generic therapeutics focused on the cardio-diabetic segment in india. Suri helped architect the translational network biology platform and is currently responsible for the science and business strategy at Connexios. Suri is also one of the founding directors of Group Lifespring, a human health focused group of companies (including Connexios) spanning from discovery to health care that is supported by Nadathur Holdings and Investments. Before founding Connexios in 2003, Suri was part of the founding team and headed the bioinformatics efforts at Metahelix Life Sciences Pvt. Ltd. an agribiotech company based in Bangalore. Before, his move to industry, Suri was a Research Associate in computational ecology at the Indian Institute of Science, Bangalore; a visiting scientist at the computer science department of Linkoping University, Sweden, an adjunct associate fellow at the National Institute of Advanced Studies and a LJIS Burroughs-Wellcome post doctoral fellow in computational neuroscience at the University of California, San Diego. Suri holds a Bachelors degree in Chemical Engineering from Andhra University and a PhD in condensed matter physics from the Indian Institute of Science.

K. VijayRaghavan is Senior Professor at-, and Director of- the National Centre for Biological Sciences. NCBS was established in 1992 and has grown to become one of the many quality research institutions in India. Its research interests are broad and its investigator- driven programmes cover the breadth of life sciences. NCBS has more recently, driven the development of theme- and team- driven research in its immediate environs. Notable is the recent start of the Stem Cell Institute (SCI)—a major initiative of the Indian Government’s Department of Biotechnology—whose focus will be basic and clinical research in regenerative medicine. This new Institute will be a partner of the Stem Cell Centre of the Christian Medical College Vellore where the focus will be on clinical and translational research on mesenchymal stem cells. VijayRaghavan’s own interests and in the development of nerves and muscles and how the capacity for locomotion emerges during development.

Dr Walton is a business services and media entrepreneur who through several businesses has generated over $50 million in revenues over 15 years. Dr Walton gained broad commercial experience whilst holding management positions at Bass and Celltech. In particular he was involved in contract research and licensing agreements with European, Japanese and US corporations. As an entrepreneur, Dr Walton co-founded CONNECT Pharma, a company focused on assisting pharmaceutical and biotechnology companies worldwide in all aspects of deal making including strategic alliances, Mergers & Acquisitions and equity financing. In 1997 the company became PharmaVentures. His company has worked with clients on a global basis, delivering more than 400 assignments. As a publisher, Dr Walton established CONNECT Pharma Reports, PharmaVentures Reports and PharmaDeals – a broad range of publications and databases serving the commercial and business aspects of the pharmaceutical and biotech sectors. Today, PharmaVentures is a profitable business comprising over 35 individuals with a wealth of experience in the pharmaceutical, biotechnology and associated industries and scientists from both industry and charitable organisations. Together the team’s experience offer an in-depth knowledge providing second-to-none support to our clients who are based 50% in the USA, 40% in the EU and 10% in Australia/New Zealand/Japan. In April 2008, PharmaVentures was the transactional advisor to The Dow Chemical Company for the sale of Dowpharma’s small molecules business to Dr Reddy’s in India. In 2006, Dr Walton established PharmaTelevision the world’s first on-demand television channel dedicated to the life sciences and medical sectors. PharmaTelevision produces weekly interviews with key executives in the pharmaceutical industry including Merck, J&J, AstraZeneca, Roche and Bristol-Myers Squibb. Dr Walton is an invited speaker at many leading industry events speaking on a range of topics including how organisations can drive greater value from their deals, these include; Drug Delivery Partnerships, Strategic Alliances, Business Development and Outsourcing.

Prof. Dr. Dr. h.c. Rolf G. Werner is Corporate Senior Vice President of the Corporate Division Biopharmaceuticals at Boehringer Ingelheim GmbH and responsible for the strategic orientation and the worldwide business of biopharmaceuticals of Boehringer Ingelheim. He obtained his M.Sc. in biology at University of Tübingen in 1971. After his scientific work at the Max-Planck Institute for Molecular Genetics in Berlin he obtained his PhD at University of Tübingen in 1973. In 1982 he became editorial consultant of the journal “Drug Research” and reviews more than 50 scientific publications a year. In 1990 he was appointed as professor at the Faculty of Biology at the University of Tübingen. In 1990 he also became member of the Scientific Board of Biotechnology at the University of Stuttgart and member of the Kuratorium of the Fraunhofer Gesellschaft in Stuttgart. In December 2003 he was appointed as a member of the Board of Trustees of the Boehringer Ingelheim Deutschland GmbH. In January 2004 he received an honorary doctor degree from the University of Chiang Mai in Thailand.

Scott M. Wheelwright, Ph.D., is founder and principal of the firm Strategic Manufacturing Worldwide, Inc., a consulting firm focused on developing biopharmaceuticals in Asia. Dr. Wheelwright has over twenty years experience in bringing novel products to market with work experience that encompasses pharmaceutical firms and both large and small biotech companies. Dr. Wheelwright received his Ph.D. in chemical engineering from the University of California at Berkeley and performed post-doctoral studies at the Max Planck Institute for Biophysics in Frankfurt, Germany. He is the author of a book on protein purification and has published numerous articles on manufacturing and process development.

Dr. Winkler is currently the Senior Vice President of Strategic Initiatives with a broad range of responsibilities for new business initiatives including the development of Asian markets, M&A, corporate branding and global government relations. He joined Biogen Idec in Cambridge, MA, in 1988 as research scientist. Since joining the company he has developed Amevive, an immunomodulator for the treatment of psoriasis, and held various managerial positions in clinical development, program management, and corporate administration. Dr. Winkler was born and educated in Austria, and holds an M.S. and Ph.D., in biochemistry, from the University of Vienna. He completed his postdoctoral research at the University of Medicine and Dentistry of New Jersey. His academic achievements include discoveries related to structure-host relationship of flavivirus proteins, has published more than 30 articles, and received an award for innovative research from the Austrian Society of Microbiology.

Norman has a BSc degree in Chemistry and a Ph.D. degree in Microbial Chemistry from the University of Manchester, UK. Norman joined Pfizer Sandwich in 1975 as a Biochemist in the International Process Development Group. In the next 8 years he held a number of positions in Manufacturing, Development and PGRD before joining International Manufacturing in New York in 1984. By 1996 he was the group's Executive Director, Operations and Technology and is currently Vice President, Team Leader Global Technology, where he is responsible for Global Manufacturing Services, Pfizer Global Engineering and Right First Time. Norman enjoys golf, soccer and photography. He is a Fellow of the Royal Society of Chemistry and a member of PhRMA.

Kurt Wüthrich is currently Cecil H. and Ida M. Green Professor of Structural Biology at The Scripps Research Institute, La Jolla, CA, USA and Professor of Biophysics at the ETH Zurich, Zurich, Switzerland. His research interests are in molecular structural biology, and in structural genomics. His specialty is nuclear magnetic resonance (NMR) spectroscopy with biological macromolecules, where he contributed the NMR method of three-dimensional structure determination of proteins and nucleic acids in solution. The Wüthrich groups have solved more than 70 NMR structures of proteins and nucleic acids, including the immunosuppression system cyclophilin A−cyclosporin A, the homeodomain−operator DNA transcriptional regulatory system, and prion proteins from a variety of species. Kurt Wüthrich was born in Switzerland on October 4, 1938, is married to Marianne Briner, and has two children, Bernhard Andrew and Karin Lynn. He studied chemistry, physics and mathematics at the University of Bern from 57−62, obtained the Eidgenössiches Turn- und Sportlehrerdiplom and a Ph.D. in inorganic chemistry with Prof. Silvio Fallab at the University of Basel in 64, was a postdoctoral fellow in Basel (Prof. S. Fallab), at the University of California in Berkeley, CA, USA (Prof. R.E. Connick) and at Bell Telephone Laboratories in Murray Hill, NJ, USA (Dr. R.G. Shulman) before joining the ETH Zürich in 69 (Privatdozent 70, Assistant Professor 72, Associate Professor 76, Professor of Biophysics 80, Chairman of the Department of Biology 95−00). Since 2001 he shares his time between the ETH Zürich and The Scripps Research Institute. Kurt Wüthrich’s achievements have been recognized by the Prix Louis Jeantet de Médecine, the Kyoto Prize in Advanced Technology, the Nobel Prize in Chemistry, and by a number of other awards and honorary degrees.

Roger E. Wyse joined Burrill in 1998 and has led the development of Burrill & Company’s agriculture, nutraceuticals, health & wellness, and industrial biotechnology related activities in venture capital investing, and merchant banking. Dr Wyse is an internationally recognized scientist and was a Dean at two major research universities, Rutgers and the University of Wisconsin-Madison. Immediately prior to joining Burrill & Company, Dr. Wyse served for five years as Dean of the College of Agricultural and Life Sciences at the University of Wisconsin-Madison. From 1986 to 1992 he served as Dean of Research at Rutgers University. Throughout his administrative career Dr. Wyse has been known for his vision and leadership in developing national policies and funding for life sciences research. Dr Wyse chairs or serves on the boards of eight private companies (Attune, Brand New Brands, Corazonas, CreAgri, Dreamerz, Efficas, LightFull, and Natural Dentist). He is Co-Chairman of the newly formed Malaysian Life Sciences Capital Fund; and is a member of the International Advisory Panel for Biotechnology (BioIAP) for the Prime Minister of Malaysia. He was founder and Chairman of the Alliance for Animal Genome Research. In research, Dr. Wyse earned international recognition for his basic studies in plant biochemistry. He has published over 150 scientific papers. In recognition of his research accomplishments he received the prestigious Arthur Flemming Award in 1982 as the Outstanding Young Scientist in the US Federal Service. He was elected a Fellow of both the Crop Science Society of America and The American Society of Agronomy. He has also served as a consultant to numerous Fortune 500 companies. Dr. Wyse is sought after as a speaker and advisor on biotechnology: trends, issues, market opportunities, and financing.

Patrick Y. Yang is executive vice president, Product Operations. In this role, he is responsible for Genentech's Engineering, Manufacturing, Regulatory, Quality & Compliance, Facilities, Supply Chain Management, and Manufacturing Collaboration functions. Yang is a member of Genentech's executive committee. Yang joined Genentech in 2003 as vice president, South San Francisco Manufacturing and Engineering and most recently served as senior vice president, Product Operations. Prior to joining Genentech, Yang spent 11 years at Merck & Company in various leadership positions. Most recently, he held the position of vice president, Supply Chain Management in Merck's Manufacturing Division. In this role, he led the worldwide materials management, planning, global procurement, distribution/logistics, management engineering, third party manufacturing, automation and manufacturing support functions for Merck's manufacturing plants around the globe. Previous to that position, he was Merck's vice president, Asia/Pacific Manufacturing Operations. Yang was promoted to senior vice president, Product Operations in December 2004. In January 2006, Yang was promoted to executive vice president. Prior to joining Merck in 1992, Yang spent 12 years at General Electric, serving in several research, engineering, technology, and manufacturing leadership roles with an increasing scope of responsibilities. Before working for General Electric, Yang spent five years in aerospace control systems research and development with Life Systems, Inc. Yang holds a Bachelor of Science from the National Chiaotung University in Taiwan, a Master of Science in electrical engineering from the University of Cincinnati, and a doctorate in electrical engineering and computer science from Ohio State University.

Dr. Yokoyama joined ReproCELL Inc., Japan-base stem cell biotechnology company, in 2004 as a general manager of business development division and became Chief Executive Officer in 2005. He has been responsible for all aspects of new product management, alliance, and fund raising. In 2005, he also participated in establishing a non-profit research organization, Stem Cell and Drug Discovery Institute, in which human ES cell research is intensively carried out for the purpose of drug discovery and toxicity testing applications, and became the president. From 1996 to 2004, he worked for McKinsey and Company Inc. as a management consultant and then for Sumitomo 3M, a subsidiary of 3M, to serve as a R&D leader of a new project. He received his Ph.D. in chemistry from Tokyo University in 1996.

Dr. Yu is VP of strategy at Wuxi Pharmatech. She has 15 years of experience in venture capital and the life sciences industry. Most recently she co-lead Pfizer’s venture capital group in New York. While at Pfizer she was instrumental in work in diverse areas such as diagnostics, asset monetization and creative finance structures and Pfizer’s innovation agenda. Previously, she was a General Partner at Delphi Ventures and a Managing Director at Bay City Capital, two leading bay area venture firms focused on the life sciences. Debra also spent four years at Mckinsey in New York and London. She has held positions at the FDA, The Wilkerson Group, Morgan Stanley and Genentech. She has stewarded more than 25 companies through venture capital, sat on the board of 8 and stepped in as CEO of one. Debra also served as a Director of the Permanente Company, part of Kaiser Permanente and helped build its corporate venture efforts. Debra received a B.A. with high honors in Molecular Biology from Princeton in 1986 and earned an M.D. from Harvard Medical School in 1992.

Gordon (Gang) Zong has over eighteen years of experiences in life sciences research, technology commercialization, business consulting, and new venture startup. He has written grant-winning research proposals, award-winning business plan, and published papers in top ranked scientific journals. He has done over a hundred licensing and collaboration deals and has been actively involving in forming high-tech and biotech startups, formed several startup companies including two startups with US Venture Capital funding, and is experienced with drug development, regulatory, intellectual property, licensing, and startup financing and management issues. His main work experiences include 5 years of cancer research and 5 years of technology transfer and business development at The University of Texas MD Anderson Caner Center – the Number 1 ranked cancer center in the US, and over 6 years of teaching and managing technology transfer at Shanghai Institutes for Biological Sciences. His scientific expertise includes tumor suppressor genes, cancer drug development, drug delivery systems, gene therapy, animal tumor models, cell culture, and genome mapping. Gordon holds a BS in Biochemistry from Xiamen University, an MS in Biochemistry and Molecular Biology from The University of Texas Graduate School of Biomedical Sciences at Houston, an MBA in Entrepreneurship and Marketing from Graduate School of Business at The University of Texas at Austin, and is completing his Ph.D. in Health Economics and Biological Sciences from The University of Texas Health Science Center at Houston.